Document:

Internet Capital Group, Inc. Compensation Clawback Policy

 Exhibit 10.1 

INTERNET CAPITAL GROUP, INC. 

COMPENSATION CLAWBACK POLICY 

Effective as of April 12, 2010 

In addition to any other remedies available to Internet Capital Group, Inc. (together with its subsidiaries, “ICG”), if the
Board of Directors of Internet Capital Group, Inc. (the “Board”) (or, at the discretion of the Board, a duly authorized committee of the Board) determines in its sole discretion that it is appropriate, ICG may recover (in whole or in part)
any performance-based bonus or other incentive-based compensation paid to any officer of ICG after the date hereof to the extent that such bonus or compensation is based upon any financial results that were impacted by such officer’s fraud or
intentional misconduct.Summary of 2010 Amendments

 Exhibit 10.1 

Summary of 2010 Amendments to the 

Energy Partners, Ltd. Change of Control Severance Plan 

Amend the Change of Control Severance Plan effective as of March 24, 2005, as amended from time to time prior to the date hereof,
for designated officers and employees of the Company (the “COC Plan”) to provide for the following: 

(i) Provide that a Participant (as defined in the COC Plan) receives benefits under the COC Plan only if such
Participant’s termination of employment occurs within one year after a Change of Control (as defined in the COC Plan); 

(ii) Provide for levels of Designated Multiple (as defined in the COC Plan) of 1.0, 1.5, 2.0 and 2.5; 

(iii) Provide for levels of Designated Period (as defined in the COC Plan) of: 

 

	 	(A)	12 months for Participants with a Designated Multiple of 1.0; and 

  

	 	(B)	18 months for Participants with a Designated Multiple of 1.5, 2.0 or 2.5; 

(iv) Change the method of determining a Participant’s bonus for purposes of calculating the severance benefit payable
as follows: 
  

	 	(A)	for a termination of employment occurring during 2010, 50% of the target bonus for 2010; 

 

	 	(B)	for a termination of employment occurring during 2011, the average of (1) 50% of the target bonus for 2011, (2) 50% of the target bonus for 2011 and
(3) the actual bonus paid or to be paid for 2010; 

  

	 	(C)	for a termination of employment occurring during 2012, the average of (1) 50% of the target bonus for 2012, (2) the actual bonus paid for 2010 and
(3) the actual bonus paid or to be paid for 2011; 

  

	 	(D)	for a termination of employment occurring after 2012, the average annual bonus for the three years preceding termination; and 

	 	(E)	for a termination of employment of a Participant hired after the adoption of this proposed amendment of the COC Plan, the Board and/or the Compensation Committee can
determine to adjust the bonus calculation if, under the circumstances of such Participant’s employment, the Board and/or Compensation Committee determines such adjustment is necessary or appropriate to accomplishing the objectives of the COC
Plan; and 

 (v) For a period of 18 months after the adoption of this proposed amendment of the COC
Plan, no amendment or termination of the COC Plan is permitted that would remove a Participant from the COC Plan or would adversely affect a Participant’s rights to benefits under the COC Plan, other than to define an exchange offer, bankruptcy
or similar technical circumstance as not constituting, in the determination of the Board, a Change of Control, in terms of fulfilling the objectives of the COC Plan. 

 

 - 2 -Summary of 2010 Amendments to the Employment Agreement

 Exhibit 10.2 

Summary of 2010 Amendments to the Employment Agreement 

Between Energy Partners, Ltd. and Gary Hanna 

Amend the Employment Agreement dated as of October 1, 2009 by and between the Company and Gary Hanna, the Chief Executive Officer of
the Company (the “CEO Employment Agreement”), as follows: 
  

	 	(a)	Termination Without Cause 

  

	 	(i)	The CEO Employment Agreement currently provides for six months’ severance if he is terminated without cause. 

 

	 	(ii)	This provision would be modified so that the amount of severance for termination without cause would be equal to 18 months’ Base Salary (as defined in the CEO
Employment Agreement). 

  

	 	(b)	Evergreen Provision 

 An
“evergreen” provision would be added to the CEO Employment Agreement so that, if necessary at the end of any month, an additional period is added to the Term (as defined in the CEO Employment Agreement) so that Mr. Hanna always has at
least 18 months remaining on his Term as of the end of any month. 
  

	 	(c)	Change of Control 

  

	 	(i)	In light of the designation by the Board of Mr. Hanna as a participant in the COC Plan, the CEO Employment Agreement will need to be modified to adjust for this
change. 

  

	 	(ii)	Specifically, certain of the termination benefit provisions in the CEO Employment Agreement will need to be adjusted so that Mr. Hanna does not receive duplicative
or overlapping change of control benefits. 

  

	 	(iii)	Furthermore, express language will be added to the CEO Employment Agreement guaranteeing that Mr. Hanna will not lose the benefit of the COC Plan, even if it is
subsequently amended or terminated. 

  

	 	(d)	CEO’s Primary Office 

 In
order to clarify certain matters regarding the location of Mr. Hanna’s primary office, the CEO Employment Agreement will be further amended in a manner consistent with Appendix I to this Exhibit 10.2, which is attached
hereto. 

 Appendix I 

To Exhibit 10.2 

CEO’s Primary Office 

The parties desire to amend the CEO Employment Agreement as follows to reflect that Mr. Hanna is and will continue to be based in the Company’s
Houston office, is under no obligation to relocate to New Orleans, and is entitled to reimbursement for the costs of traveling to New Orleans from Houston: 

a. The second sentence of the second paragraph of Section 2 of the CEO Employment Agreement is hereby deleted, effective as
of the Effective Date. 
 b. Effective as of the Effective Date, Section 3(f) of the CEO Employment Agreement is
hereby amended and restated to read in its entirety as follows: 
 “(f) Following the first year of the
Initial Term, if the Company’s primary offices remain in New Orleans, Executive may move from the Company’s Houston office to the Company’s New Orleans office and, in the process, relocate to New Orleans, Louisiana. Upon such
relocation, the Company shall reimburse Executive for moving expenses and normal closing costs (fees, appraisal, commissions, etc.) related to the sale of Executive’s current residence in Houston, Texas. The total amount of such relocation
expenses reimbursable pursuant to this Paragraph 3(f) shall not exceed $100,000; provided, however, that the Company shall not be obligated to reimburse Executive for any such relocation expenses unless Executive (i) has taken
steps toward relocating to New Orleans on or before the first anniversary of the Effective Date, and (ii) does in fact relocate to New Orleans within a reasonable time thereafter.”Enzyme and Product Supply Agreement

 EXHIBIT 10.7B 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 
 Execution Copy 

ENZYME AND PRODUCT SUPPLY AGREEMENT 

THIS ENZYME AND PRODUCT SUPPLY AGREEMENT, including the exhibits attached hereto (the
“Agreement”), effective as of February 16, 2010 (the “Effective Date”), is made and entered into by and between Codexis, Inc., a Delaware corporation, having a place of business at 200 Penobscot Drive,
Redwood City, California 94063, United States of America (“Codexis”), and Arch Pharmalabs Limited, a corporation organized and existing under the laws of India having a place of business at H wing,
4th Floor, Tex Centre, Chandivali, Mumbai, 400072, India
(“Arch”). Codexis and Arch each may be referred to herein individually as a “Party,” or collectively as the “Parties.” 

WHEREAS, Codexis has proprietary rights in certain enzymes, chemical synthesis and biocatalysis process technology, and possesses
certain valuable business and/or technical knowledge, information, and/or expertise, relating to enzymatically catalyzed manufacturing processes; 

WHEREAS, Arch has expertise and facilities for the manufacture of bulk pharmaceutical active ingredients and/or intermediates
thereof by chemical synthetic routes; 
 WHEREAS, Codexis, Arch, and Codexis Laboratories India Private Limited entered
into a certain Enzyme License and Development Agreement, Enzyme Supply Agreement, Product Supply and Marketing Agreement, and certain other agreements related thereto, each effective as of August 21, 2008 (collectively, the “2008 Arch
Agreements”); and 
 WHEREAS, the Parties are simultaneously terminating the 2008 Arch Agreements and entering
into this Agreement whereby Codexis desires to grant certain rights to Arch to use proprietary technology of Codexis and supply certain proprietary enzymes to Arch for the purpose of manufacturing, promoting and marketing bulk active pharmaceutical
ingredients and/or intermediates thereof for sale by Codexis to Codexis Customers and for sale by Arch to Arch Customers, as more fully set forth in this Agreement. 

NOW, THEREFORE, in consideration of the mutual covenants and obligations set forth herein, and for other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows: 
 1. DEFINITIONS 

As used in this Agreement, the following terms are defined as indicated: 

1.1 “2008 Arch Agreements” shall have the meaning set forth in the Recitals. 

1.2 “Affiliate” shall mean, in respect of any Party or Third Party, any entity that is controlled by, controls, or is
under common control with such Party (or Third Party) on or after the Effective Date, as the case may be, but only for so long as such entity remains an Affiliate under this Section 1.2. For purposes of this Section 1.2, the term
“control” means (a) direct or 

 
indirect ownership of more than fifty percent (50%) of the voting interest in the entity in question, or more than fifty percent (50%) interest in the income of the entity in question;
provided, however, that, if local law requires a minimum percentage of local ownership of greater than fifty percent (50%), control will be established by direct or indirect beneficial ownership of one hundred percent (100%) of
the maximum ownership percentage that may, under such local law, be owned by foreign interests, or (b) possession, directly or indirectly, of the power to direct or cause the direction of management or policies of the entity in question
(whether through ownership of securities or other ownership interests, by contract or otherwise). 
 1.3 “Active
Pharmaceutical Ingredient(s)” or “APIs” shall mean chemicals used in the manufacture of drugs and do not include intermediates used in the manufacture of such chemicals. 

1.4 “Applicable Law” shall mean all laws, statutes, ordinances, codes, rules, and regulations that have been
enacted by a Government Authority and are in force as of the Effective Date or come into force during the Term, in each case to the extent that the same are applicable to the performance by the Parties of their respective obligations under this
Agreement. 
 1.5 “Arch Bio-Chemical Improvements” shall have the meaning set forth in
Section 11.1.2 . 
 1.6 “Arch Chemical Improvements” shall mean any discovery, contribution,
method, finding, or improvement, whether or not patentable, and all related intellectual property that is individually or jointly conceived, invented, reduced to practice, or developed by Arch and/or its Affiliates in connection with this Agreement
using solely chemistry steps without involving any bio-chemical conversion and which do not relate to any Codexis IP Rights, Codexis Process, Codexis Enzymes or Codexis Improvements (the “Arch Chemical Improvements”). 

1.7 “Arch Customers” shall mean (i) Affiliates of Arch within India, including Vitalife; (ii) Third
Party Generic Companies that do not fall within Codexis Customers or Codexis India Customers; and (iii) unless otherwise specified by Codexis, Codexis India. 

1.8 “Arch Trademarks” shall mean the trademarks, tradenames, designs and logos set forth on Exhibit 1.8.

 1.9 “Batch” shall mean, on a Product-by-Product basis, a specific quantity of Product intended to be of
uniform character and quality and produced during the same cycle of manufacture, as defined by the master batch record for such Product, and which is manufactured in accordance with the terms of this Agreement. 

1.10 “Business Day” shall mean any day that is not a Saturday or a Sunday or a day on which the New York Stock Exchange
is closed. 
 1.11 “Buy-Out Event” shall mean any of the following events: (a) Codexis filing for
bankruptcy or insolvency under Applicable Law (in which case the Buy-Out Event shall apply to all Codexis Enzymes (and the corresponding Products) which Codexis was supplying to Arch as 

 

 2 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
of the date of such filing); (b) Expiration (but not early termination) of the Term of this Agreement (in which case the Buy-Out Event shall apply only to the Codexis Enzyme(s) (and
corresponding Product(s)) for which Codexis’ obligation to supply to Arch have expired); (c) failure by Codexis to supply Codexis Enzyme pursuant to Section 2.14 (in which case the Buy-Out Event shall apply only to the Codexis
Enzyme(s) (and corresponding Products) which Codexis failed to supply pursuant to Section 2.14); and (d) Codexis determines that it is not commercially feasible to supply Codexis Enzyme in accordance with Section 4.1(a) (in which case the
Buy-Out Event shall apply to the Codexis Enzyme(s) (and corresponding Products) which Codexis made such determination pursuant to Section 4.1(a)). 

1.12 “Calendar Quarter” shall mean the respective periods of three (3) consecutive calendar months ending on
March 31, June 30, September 30 and December 31; provided, however, that (a) the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first complete Calendar
Quarter thereafter; and (b) the last Calendar Quarter of the Term shall end upon the expiration or termination of this Agreement. 

1.13 “cGMP” shall mean the current Good Manufacturing Practices regulations and implementing guidelines and General
Biological Products Standards promulgated by the FDA and published at 21 CFR §§ 210, 211 and 610, as such regulations may be amended from time to time, and by the European Commission as set out in Directive 91/356 EEC of the Commission of
the European Communities as may be amended from time to time and all relevant foreign equivalents, to the extent such regulations apply to “API intermediates” and/or “API Bulk Drug” as defined in QA7 of the Quality Guidelines of
the International Conference on Harmonization. 
 1.14 “Change” shall have the meaning set forth in
Section 3.12.2. 
 1.15 “Claim” shall have the meaning set forth in Section 13.1 or 13.2, as
applicable. 
 1.16 “Codexis Customers” shall mean (i) Third Party Innovator Companies located throughout
the world (other than in India); and (ii) Third Party Generic Companies located in United States, Canada, and Israel, and their respective commonwealths, territories and possessions, and Europe. 

1.17 “Codexis Enzyme” shall mean, on a Product-by-Product basis, the respective enzyme(s) set forth on Exhibit
1.17 as of the Effective Date or added at any time during the Term pursuant to an amendment of Exhibit 1.17 made in accordance with Section 16.9. 

1.18 “Codexis Enzyme-Related Restrictions” shall have the meaning set forth in Section 2.15. 

1.19 “Codexis Improvements” shall mean, on a Product-by-Product basis, (i) any modifications, changes, additions,
variations, derivatives, alterations or improvements to the respective Codexis Enzyme(s) (other than new or improved Codexis Enzymes covered by Section 2.5) and/or Codexis Process(es), which are individually or jointly developed by Codexis
and/or its Affiliates, whether patentable or not, during the Term of this Agreement; and (ii) Arch Bio-Chemical Improvements. 

1.20 “Codexis India” shall mean Codexis Laboratories India Private Limited. 

 

 3 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 1.21 “Codexis India Customers” shall mean (i) Third Party
Innovator Companies in India; and (ii) the following companies in India: [*], as the foregoing list may be updated or modified pursuant to written agreement of the Parties. 

1.22 “Codexis IP Rights” shall mean, on a Product-by-Product basis, any technology, Information, expertise, know-how,
trade secrets, Patents and/or other intellectual property rights (excluding any trademarks, including without limitation, the Codexis Trademarks) Controlled by Codexis and/or its Affiliates and necessary for or otherwise used in the manufacture of
Product. 
 1.23 “Codexis Process” shall mean, on a Product-by-Product basis, any process and/or method(s) of
use of a Codexis Enzyme, including without limitation, any in vitro biochemical conversion of a chemical substrate into the respective Product catalyzed by the respective Codexis Enzyme, or any analog or homolog thereof, developed or supplied by or
on behalf of Codexis pursuant to this Agreement. For avoidance of doubt, the Codexis Process shall not include any Arch Chemical Improvements. 

1.24 “Codexis Trademarks” shall mean the trademarks, tradenames, designs and logos set forth on Exhibit 1.24.

 1.25 “Confidential Information” shall mean any Information of a confidential and/or proprietary nature,
including without limitation the know-how, information, invention disclosures, patent applications, proprietary materials and/or techniques, economic information, business or research strategies, purchase orders (and any information included
therein), trade secrets, and material embodiments thereof, disclosed by a Party to the other Party in written form marked “confidential,” or in oral form if summarized in a writing marked “confidential” and delivered to the
Receiving Party within thirty (30) days after such oral disclosure. For purposes of this Agreement, any and all Codexis Enzymes and Codexis Processes shall be deemed to be Confidential Information of Codexis. 

1.26 “Control” shall mean, with respect to an intellectual property right, possession of the ability, whether arising by
ownership or license, to grant a license or sublicense as provided for in this Agreement under such right, or, with respect to an item, possession of the ability, whether arising by ownership or license, to transfer such item as provided for in this
Agreement, in each case, without violating the terms of any written agreement with any Third Party. 
 1.27 “Disclosing
Party” shall have the meaning set forth in Section 10.1. 
 1.28 “Disputes” shall have the
meaning set forth in Section 14.1. 
 1.29 “Drug Master File” or “DMF” shall
mean Arch’s Drug Master File for manufacturing the applicable API as defined and filed with the FDA, and the equivalent filing with the governing health authority of any country in the European Union. 

1.30 “Enzyme Purchase Order” shall have the meaning set forth in Section 2.7. 

1.31 “Enzyme Rolling Requirement Forecast” shall have the meaning set forth in Section 2.6. 

 

 4 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 1.32 “Enzyme Specification” shall have the meaning set forth in Section
2.14 
 1.33 “Europe” shall mean all member States of the European Union and all countries included in
the European Economic Area as of the Effective Date, and Switzerland, Turkey, and Croatia and other countries formerly part of Yugoslavia. 

1.34 “Execution Audit” shall have the meaning set forth in Section 2.16. 

1.35 “FDA” shall mean the U.S. Food and Drug Administration and any successor agency. 

1.36 “First Commercial Sale” shall mean, on a Product-by-Product basis, the first sale by a Party of any quantity of a
Product used in or intended for use in any drug product approved for marketing in the United States or Europe. 
 1.37
“Government Authority” shall mean any supranational, national, regional, state or local government, court, governmental agency, authority, board, bureau, instrumentality, regulatory body, or other government entity, including without
limitation any of the foregoing that is involved in the granting of approvals, licenses, registrations, or authorizations for commercialization of the Product and/or of drug product containing the Product. 

1.38 “Information” shall mean data, results, inventories, information, inventions, know-how, processes, machines, trade
secrets, techniques, methods, developments, materials, or compositions of matter or other information of any type or kind. 

1.39 “Manufacturing Facility” shall mean any site or plant in which Arch manufactures Product in accordance with the
provisions of this Agreement. 
 1.40 “MSA” shall mean that certain Master Services
Agreement, entered into by Codexis and Arch and effective as of August 1, 2006, as amended. For the avoidance of doubt, neither the MSA nor any amendment to the MSA shall fall within the definition of 2008 Arch Agreements. 

1.41 “Non-Codexis Process” shall mean, on a Product-by-Product basis, in whole or in part, any chemical and/or
manufacturing methods, processes, procedures, and/or techniques (excluding Codexis Process), which are individually or jointly conceived, invented, reduced to practice, or developed by Arch and/or its Affiliates, in connection with this Agreement,
whether patentable or not, and any improvements and/or modifications thereto, in each case as necessary for or otherwise used in the manufacture of Product. 

1.42 “Non-Exclusive Relationship” shall have the meaning set forth in Section 4.2. 

1.43 “Option” shall have the meaning set forth in Section 15.5. 

1.44 “Patent” shall mean: (a) issued letters patent, including extensions, supplemental protection certificates,
registrations, confirmations, reissues, reexaminations or renewals thereof; and (b) pending applications, including any provisional applications, converted provisional 

 

 5 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
applications, continuing prosecution applications and continuation, divisional, or continuation-in-part applications thereof, for any of the foregoing. 

1.45 “Products” shall mean the API and intermediate products set forth on Exhibit 1.45 as of the Effective Date
or added at any time during the Term pursuant to an amendment of Exhibit 1.45 made in accordance with Section 16.9. 

1.46 “Product Purchase Order” shall have the meaning set forth in Section 3.6. 

1.47 “Product Specification” shall have the meaning set forth in Section 3.12.1 . 

1.48 “Receiving Party” shall have the meaning set forth in Section 10.1. 

1.49 “Term” shall have the meaning set forth in Section 15.1. 

1.50 “Third Party” (and with its correlative meaning, “Third Parties”) shall mean any party other than
Codexis, Arch, or an Affiliate of either Codexis or Arch. 
 1.51 “Third Party Generic Company” shall mean, on
a Product-by-Product basis, all Third Party pharmaceutical companies other than Third Party Innovator Companies, and their permitted licensees, successors and assigns (provided such licensees, successors and assigns are not Third Party Innovator
Companies). 
 1.52 “Third Party Innovator Company” shall mean, on a Product-by-Product basis, (i) all
Third Party pharmaceutical companies that either have, or have had, a proprietary interest in the composition of matter of the respective Product; and (ii) any Third Party pharmaceutical company which does not have, or have had, a proprietary
interest in the composition of matter of the respective Product but which company primarily sells products in which it has or has had a proprietary interest therein as opposed to products in which it has or has had no proprietary interest, in each
case, together with their permitted licensees, successors and assigns. 
 2. ENZYME PURCHASE AND SUPPLY; LICENSE GRANTS 

2.1 Codexis Enzymes. Subject to the terms and conditions of this Agreement, including without limitation Section 4.1, on a
Product-by- Product basis, Arch (and its Affiliates) shall purchase exclusively from Codexis (or its Affiliates) quantities of applicable Codexis Enzyme sufficient to enable Arch (or its Affiliates) to manufacture the respective Products. Subject to
Section 4.1, Codexis (and its Affiliates) shall not supply Codexis Enzymes to any other Third Party for purposes of manufacturing Products and Arch (and its Affiliates) shall not acquire any enzyme for use in the manufacture of Products from
any Third Party. Notwithstanding the foregoing, 
 (i) Codexis (or its Affiliates) may supply [*] to one Third Party that
may use [*] for the purposes of manufacturing and selling [*]; provided, Codexis (or its Affiliates, as the case may be) ensures by way of written contract that such Third Party is bound not to sell the [*] intermediate, that
may be manufactured utilizing the same Codexis Enzyme ([*]). 
  

 6 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 (ii) Codexis (or its Affiliates) may supply [*] to one Third Party that may use
[*] for the manufacture of [*]. 
 2.2 License Grants to Arch. 

(a) Codexis IP Rights. Subject to the terms and conditions of this Agreement, Codexis hereby grants to Arch on a
Product-by-Product basis, during the Term a non-exclusive, non-sublicensable and non-transferable (subject to Section 16.6) license under the Codexis IP Rights to use the Codexis Enzyme(s) and/or Codexis Process(es) (but not the Codexis
Improvements) solely to manufacture Products for sale by Codexis to Codexis Customers and for sale by Arch to Arch Customers. 

(b) Codexis Improvements. Subject to the terms and conditions of this Agreement, Codexis hereby grants to Arch on a
Product-by-Product basis, during the Term, a non-exclusive, non-sublicensable and non-transferable (subject to Section 16.6) license under the Codexis IP Rights to use the Codexis Improvements Controlled by Codexis which are necessary for the
manufacture and sale of Products, solely to manufacture Products for sale by Codexis to Codexis Customers and for sale by Arch to Arch Customers. 

2.3 Enzyme Specification. The specification for each Codexis Enzyme (each, an “Enzyme Specification”) is as set
forth in Exhibit 2.14. All Codexis Enzymes supplied by Codexis hereunder shall comply with the applicable Enzyme Specification. 

2.4 Supply Obligation of Codexis. Subject to the terms and conditions of this Agreement, during the Term, Codexis shall supply (or
have supplied by its designees) Codexis Enzymes to Arch to be used by Arch solely in the manufacture of Products (A) sold by Arch to Arch Customers and (B) sold to Codexis for sale by Codexis to Codexis Customers. 

2.5 New or Improved Enzymes. On a Product-by-Product basis, Codexis shall provide Arch with its projected commercial availability
date for any improved Codexis Enzyme(s) for existing Product(s) at least six (6) months prior to Codexis’ projected ability to manufacture at least one hundred (100) kilograms of each such Codexis Enzyme and upon designation by
Codexis, such improved Codexis Enzyme shall be added to Exhibit 1.17 and fall within the definition of Codexis Enzyme. 

2.6 Enzyme Rolling Requirement Forecasts. On a Product-by-Product basis, beginning three (3) months prior to the anticipated
First Commercial Sale to a Third Party of at least one hundred (100) kilograms of Product until the end of the Term, at least thirty (30) days prior to the beginning of each Calendar Quarter, Arch shall provide Codexis a written forecast
of Arch’s expected requirements for each of the Codexis Enzyme(s) based on Arch’s good faith projected sales of Products, during the following twelve (12) calendar months broken down by calendar months, and which shall include
projected order dates, quantities, shipping dates, and quality standards (as applicable) (each, an “Enzyme Rolling Requirement Forecast”). 

2.7 Enzyme Purchase Orders. Each of the Codexis Enzyme(s) shall be ordered by Arch by written purchase order delivered by email
(or by any other means agreed by the Parties), in a form to be mutually agreed by the Parties (each, an “Enzyme Purchase Order”). No 

 

 7 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
communications (oral, electronic, written or otherwise) between the Parties in respect of any purchase or supply of Codexis Enzymes shall be binding on the Parties except to the extent such
communication is embodied in an Enzyme Purchase Order or other document signed by each Party. At least sixty (60) days prior to the earliest desired date of delivery, Arch shall place binding Enzyme Purchase Orders for each of the Codexis
Enzyme(s) reasonably consistent with the Enzyme Rolling Requirement Forecast. Codexis shall have five (5) Business Days to accept or reject each Enzyme Purchase Order and if Codexis does not respond within such five (5) Business Days then
the Enzyme Purchase Order is deemed rejected. Notwithstanding the foregoing, any Enzyme Purchase Order placed by Arch specifying in writing that the requested Codexis Enzymes are for a confirmed Product Supply Order placed by Codexis shall be deemed
accepted by Codexis upon receipt of the same. 
 2.8 Codexis Enzyme Supply. Codexis shall ensure that the timing and
delivery of supply of Codexis Enzyme is consistent with the Enzyme Rolling Requirement Forecast and the corresponding Product Supply Orders. Codexis, at its sole cost and expense, will validate, manufacture and supply the Codexis Enzymes in
accordance with the applicable Enzyme Specification, and will be responsible for all necessary and useful requirements therefor, including without limitation ensuring sufficient manufacturing capacity, employing appropriate equipment, facilities and
personnel, implementing cost reduction plans, and complying with all Applicable Laws. The Codexis Enzymes will be manufactured and supplied to Arch under the Codexis Trademarks. 

2.9 Conflicts. To the extent that there is any conflict or inconsistency between this Agreement and any Enzyme Rolling Requirement
Forecast or Enzyme Purchase Order, the terms of this Agreement shall govern unless otherwise agreed to in writing by the Parties. For clarity, no term or condition added by Arch to an Enzyme Purchase Order shall be binding on Codexis unless such
term or condition is specifically agreed to by Codexis in writing signed by a duly authorized officer of Codexis. 
 2.10
Delivery and Storage of Codexis Enzymes. Subject to Section 2.7, Codexis shall deliver to Arch the amount of each of the Codexis Enzyme(s) specified in each Enzyme Purchase Order no later than the dates specified therein; provided,
that Codexis shall not be required to deliver such amount prior to sixty (60) days after receiving such Enzyme Purchase Order. All Codexis Enzymes shall be shipped by Codexis (or its designee) by air or as otherwise directed by Arch, to the
location designated in writing by Arch. The Parties shall cooperate in selecting appropriate carriers, and title and risk of loss shall pass to Arch upon delivery by Codexis to such carrier(s). Codexis (or its designee) shall ship each of the
Codexis Enzymes under appropriate packaging and storage conditions, including, for example, using envirotainers or similar temperature-control equipment for shipments. Arch agrees to store Codexis Enzymes in a secure location at minus twenty degrees
Celsius (-20°C) unless otherwise instructed by Codexis. Arch shall bear any and all costs arising from failure to comply with the terms of the foregoing sentence. 

2.11 Inspection of Codexis Enzyme. Codexis Enzymes shall be shipped with a mandatory certificate of analysis as per customary
industry practice. Arch shall have ten (10) days to inspect each shipment and provide a written rejection of any shipment of enzyme on the 

 

 8 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
basis that such enzyme does not comply with the applicable Enzyme Specification. In the event that Codexis receives a written notice of rejection from Arch, subject to Section 2.13, Codexis
shall replace such rejected Codexis Enzyme pursuant to Section 2.12. If Arch fails to notify Codexis in writing of a rejection within such ten (10) day period, the shipment of Codexis Enzyme shall be deemed accepted by Arch and Codexis
shall have no obligation to accept a return of or to replace such shipment. In any event, Arch shall pay for such Codexis Enzymes as otherwise provided herein and shall be entitled to, at its sole discretion, a credit or refund of the properly
rejected shipment at the time they are ultimately rejected. 
 2.12 Replacement of Defective Codexis Enzyme. In the event
that Codexis receives a written notice of rejection from Arch in accordance with Section 2.11, Codexis (or its designee) shall, at the sole cost and expense of Codexis, replace any shipment of such rejected Codexis Enzyme, including without
limitation disposal of such rejected Codexis Enzyme, within sixty (60) days after receiving Arch’s written notice of rejection. For clarity, the foregoing right shall not limit any other remedy available at law or in equity. Arch shall
keep such defective Codexis Enzyme at its premises until receipt of Codexis’ instruction for Arch to return or otherwise dispose of such defective Codexis Enzyme. Notwithstanding anything to the contrary, Codexis shall have no obligation to
replace any shipment of Codexis Enzyme or part thereof pursuant to this Section 2.12 or issue a refund or credit pursuant to Section 2.11 in the event Codexis can establish that there was no defect or such defect occurred after delivery of
such shipment of Codexis Enzyme. Codexis shall in good faith provide details to Arch of test methods that are customarily employed by Codexis to check the purity and quality of Codexis Enzymes supplied to Arch. In the case of a marginal Enzyme
Specification failure or non-compliance, the relevant Codexis Enzyme can be offered to Arch for use at a higher loading rate in the production process than dictated by the standard recipe. Under such cases, if there is increased inconvenience to
Arch in use of such Codexis Enzyme then a reduced price will be agreed to by the Parties that reflects the increased usage and inconvenience. 

2.13 Disputes. If Codexis disputes Arch’s right to reject all or part of any shipment of any Codexis Enzyme as set forth in
Section 2.11, Codexis shall notify Arch within ten (10) days after receipt of Arch’s written notice of such rejection. Such dispute shall be resolved by a Third Party within thirty (30) days of such notice. Such Third Party shall
have expertise in the area of biocatalysis, the identity of whom shall be mutually agreed upon by the Parties, and the appointment of whom shall not be unreasonably delayed or conditioned by either Party. The determination of such Third Party with
respect to all or part of any shipment of any Codexis Enzyme shall be final and binding upon the Parties. The Third Party’s scope of review and decision shall be strictly limited to the reasons given by Arch in rejecting the shipment or part
thereof, and such Third Party may not consider any alleged defects or reasons beyond the alleged defects and reasons given by Arch. For the avoidance of doubt, if such Third Party determines that the reasons given by Arch in rejecting the shipment
or part thereof were not proper, then no refund or credit shall be due to Arch under Section 2.11, even if such Third Party determines that the shipment was defective on other, independent bases. The fees and expenses of such Third Party shall
be paid by the Party against which the determination is made. Notwithstanding anything to the contrary in this Article 2, Codexis shall continue delivering Codexis Enzyme(s) pursuant to the terms of this Agreement and Arch shall pay for Codexis
Enzymes, including 
  

 9 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
without limitation replacement of any defective Codexis Enzyme, pursuant to the terms of this Agreement during the dispute resolution process set forth in this Section 2.13. 

2.14 Failure to Supply Enzyme. In the event that Codexis (and its designees) fail to supply at least [*] of the amount of
any particular Codexis Enzyme that Codexis was obligated to deliver under Section 2.7 ordered pursuant to either (i) the aggregate of all Enzyme Purchase Orders during a period of twelve (12) consecutive months or (ii) three
(3) or more Purchase Orders in any period of twelve (12) consecutive months, in accordance with the terms of such Enzyme Purchase Orders, then, notwithstanding anything to the contrary, Arch shall have the right in Arch’s sole
discretion to undertake any one of the following remedies: (a) take steps necessary to cover any such shortfall in the supply of Product that would have been manufactured using such Codexis Enzyme, including without limitation using a
manufacturing process other than the Codexis Process to manufacture the applicable Product; (b) modify any then-outstanding Enzyme Purchase Orders without penalty; (c) terminate this Agreement with respect to such Codexis Enzyme pursuant
to Section 15.2; or (d) exercise the right provided in Section 15.5 of this Agreement with respect to the Product that is manufactured using such Codexis Enzyme. Notwithstanding anything in this Agreement to the contrary, the remedies
set forth herein shall be the sole and exclusive remedies of Arch with respect to Codexis’ failure to supply Codexis Enzyme. 

2.15 Audit Rights. During the Term and for a period of three (3) years thereafter, Arch shall permit an independent technical
consultant selected by Codexis but agreed to by Arch, such agreement not to be unreasonably withheld or delayed, to have access to Arch’s records and books, and to review Arch’s manufacturing process for Product using Codexis Enzyme, at
the applicable Manufacturing Facility(ies) in order to (a) conduct an independent assessment of the performance of the Codexis Process and (b) to verify that Arch has not (i) used, sold, transferred, or produced any Codexis Enzymes,
Codexis Process, Codexis Improvements, or technology relating to the Codexis Process, including without limitation the Codexis IP Rights, in violation of the terms and conditions of this Agreement; or (ii) reverse engineered or created any
derivatives of, or made modifications and/or improvements to the Codexis Enzyme or any DNA encoding it (the “Codexis Enzyme-Related Restrictions”). Such records and books of accounting shall be kept at Arch’s principal place of
business. Such audit shall take place no more than once every twelve (12) months during regular business hours, and upon not less than ten (10) days’ written notice. Such independent auditor shall be subject to confidentiality
obligations, and such auditor shall not disclose Confidential Information of Arch to Codexis except to the extent such Confidential Information is related to the subject matter of such audit. If such examination reveals that Arch has violated any
Codexis Enzyme-Related Restriction, Codexis shall have the right, in its sole discretion, to terminate this Agreement pursuant to Section 15.2. The fees and expenses of such assessment shall be paid by Codexis, unless the examination results in
a determination that Arch has violated any Codexis Enzyme-Related Restriction, in which case Arch shall pay all reasonable costs and expenses incurred by Codexis in the course of making such determination, including the fees and expenses of such
assessment. 
 2.16 Execution Audit. Within ninety (90) days after execution of this Agreement, Arch shall permit an
independent accountant and/or technical consultant selected by Codexis to 
  

 10 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
have access to Arch’s records and books, and to review Arch’s manufacturing process for Product using Codexis Enzyme, at all Arch facilities, including without limitation the applicable
Manufacturing Facility(ies), in order to audit (a) the total physical count of Codexis Enzyme in Arch’s possession and en route to each of Arch’s facilities, (b) the total Product in Arch’s Product finished goods inventory,
and (c) the total Product being manufactured on hand (work-in-process) (“Execution Audit”). On a Codexis Enzyme-by-Codexis Enzyme and Product-by-Product basis, Arch shall deliver a complete listing of inventory of Codexis
Enzyme and Product and the location thereof at least two (2) days prior to the Execution Audit, and shall deliver a preliminary list of inventory within two (2) weeks after the execution of this Agreement. Arch shall use its best efforts
to assist the independent accountant and/or technical consultant in the Execution Audit. 
 3. PRODUCT PURCHASE AND SUPPLY; LICENSE GRANTS

 3.1 Manufacture of Products. Subject to the terms and conditions of this Agreement, including without limitation
Section 4.1, Arch shall have the exclusive right to manufacture Products using the Codexis Process and Codexis Enzymes. Arch may not use any enzymes other than Codexis Enzymes or any processes other than Codexis Processes in any step of the
manufacture of the Products unless a non-enzymatic process is the only process available for the relevant manufacturing step. For the avoidance of doubt and notwithstanding anything in this Agreement to the contrary, (i) subject to
Section 4.1, neither Arch nor its Affiliates may purchase any intermediates that fall within the definition of Products from any Third Party and (ii) Arch may purchase the intermediate [*] from Third Parties. 

(a) Products for Sale to Codexis Customers. Subject to the terms and conditions of this Agreement, including without limitation
Section 4.1, on an Product-by- Product basis, Codexis (and its Affiliates) shall purchase Products exclusively from Arch for the sale of such Product by Codexis (and its Affiliates) solely to Codexis Customers for the Term of this Agreement and
for the avoidance of doubt, Codexis (and its Affiliates) may not sell or authorize any sale of Products to any Third Party Generic Companies that are not Codexis Customers or Codexis India Customers. 

(b) Products for Sale to Arch Customers. Subject to the terms and conditions of this Agreement, on a Product-by- Product basis,
Arch may sell Products solely to Arch Customers for the Term of this Agreement and for the avoidance of doubt, Arch (and its Affiliates) may not sell or authorize any sale of Products to any (i) Third Party Innovator Companies, (ii) Third
Party Generic Companies that are Codexis Customers or (iii) Codexis India Customers. 
 3.2 License Grants to
Codexis. Arch hereby grants and shall cause its Affiliates to grant Codexis, a non-exclusive, royalty-free, non-sublicensable (except to the extent required to exercise rights under Section 4.1), non-terminable (subject to Sections
15.2 and 15.3), nontransferable (subject to Section 16.6) license under any Non-Codexis Process(es) to use, manufacture and have manufactured (subject to the restrictions set forth in Section 3.1 on Codexis’ ability to manufacture and
have manufactured Products), sell, offer for sale, import, and/or export Products to be sold by Codexis to Codexis Customers. 
  

 11 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 3.3 Supply Obligation of Arch. Subject to the terms of this Agreement, Arch shall
supply Products to Codexis to be sold by Codexis to Codexis Customers. 
 3.4 Product Supply. Arch shall label the
Products in accordance with Codexis’ written instructions as set forth in Exhibit 3.4. In accordance with Section 3, Codexis shall purchase from Arch, and Arch shall supply to Codexis Products for sale by Codexis to Codexis
Customers. The timing and delivery of such supply shall be as set forth in the applicable Product Purchase Order. Arch, at its sole cost and expense, will validate, manufacture and supply Products in accordance with the applicable Product
Specification for Product(s) to be sold to a Codexis Customer, and will be responsible for all necessary and useful requirements therefor, including without limitation ensuring sufficient manufacturing capacity; employing appropriate equipment,
facilities and personnel; implementing cost reduction plans; and complying with all Applicable Laws. The Products shall be manufactured and supplied under the Codexis Trademarks. For the avoidance of doubt, Products sold and shipped directly to
Codexis Customers will be accompanied by a Codexis Commercial Invoice and an Arch Certificate of Analysis, and any other documents as necessary or appropriate as described in the respective customer purchase order. 

3.5 Failure to Supply Product. In the event that Arch fails to deliver at least [*] of the amount of any particular Product
that Arch was obligated to deliver under Section 3.6 ordered pursuant to any particular Product Purchase Order in accordance with the terms of such Product Purchase Order, then, notwithstanding anything to the contrary, Codexis shall have the
right to take any and all steps necessary to cover, at the sole cost and expense of Arch, any such shortfall in the supply of such Product and, at Codexis’ sole discretion, to modify any then-outstanding Product Purchase Orders without penalty.
Notwithstanding and without limiting the foregoing, Arch acknowledges and agrees that: (a) any failure by Arch to deliver at least [*] of the amount of any particular Product ordered (i) pursuant to three (3) or more Product
Purchase Orders in any period of twelve (12) consecutive months or (ii) pursuant to the aggregate of all Product Purchase Orders in any period of twelve (12) consecutive months, in accordance with the terms of such Product Purchase
Orders, shall constitute a material breach of this Agreement by Arch with respect to such Product; (b) Codexis shall have the right, but not the obligation, in its sole discretion, to convert its exclusive purchase obligation (and Arch’s
exclusive manufacturing right) set forth in Section 2.1 or 4.1, as applicable, with respect to such Product to a non-exclusive arrangement (but, for clarity, in such event, Arch’s supply obligation to Codexis pursuant to Sections 2.1
and/or 4.1, as applicable, shall remain exclusive); and (c) Codexis’ rights pursuant to this Section 3.5 shall not limit any other rights of Codexis under this Agreement with respect to a failure to supply by Arch which constitutes a
material breach pursuant to paragraph (a) above, including without limitation, Codexis’ right to terminate this Agreement with respect to such Product pursuant to Section 15.2. The remedies set forth in this Section 3.5 shall be
the exclusive remedies of Codexis with respect to Arch’s failure to supply Products. 
 3.6 Product Purchase Orders.
Each of the Product(s) shall be ordered by Codexis by written purchase order submitted electronically (or by any other means agreed by the Parties), in a form to be mutually agreed by the Parties (each, a “Product Purchase
Order”). No communications (oral, electronic, written or otherwise) between the Parties in respect of any 
  

 12 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
purchase or supply of Products shall be binding on the Parties except to the extent such communication is embodied in a Product Purchase Order or other document signed by each Party. In the event
that a Codexis Customer modifies or cancels any order for Product, Codexis shall discuss the matter with Arch and only after Arch’s consent in writing (which consent may not be unreasonably withheld or delayed ) modify or cancel a Product
Purchase Order provided that Arch has not already shipped Product prior to receipt of the cancellation/modification notice. All Product Purchase Orders shall be deemed accepted by Arch, except with respect to Products subject to a Non-Exclusive
Relationship, which Purchase Orders shall be accepted by Arch only if (x) Codexis provides a sufficient quantity of Codexis Enzyme to Arch in order to allow Arch to manufacture the requested quantity of Product in the requested timeframe or
(y) accepted in writing by Arch within five (5) days of receipt of such Product Purchase Order. Arch shall promptly provide Codexis written notice in the event that Arch will not be able to deliver any quantities specified in the Product
Purchase Order. 
 3.7 Conflicts. On Product-by-Product basis and Purchase Order-by-Purchase Order basis, in the event a
Codexis Customer has additional and/or different terms and conditions regarding the supply of Product or requirement of additional sales documentation, Codexis shall forward such terms and conditions to Arch in writing, either in the applicable
Purchase Order or otherwise, and such terms and conditions shall be in addition to the terms and conditions in this Agreement solely for such Purchase Order. To the extent that there is any conflict or any inconsistency between this Agreement and
any Product Purchase Order, or any other document pertaining to the supply of Products (except as set forth in Section 3.12.3 ), the terms of this Agreement shall govern. For clarity, no conflicting term or condition added by Codexis to a
Product Purchase Order shall be binding on Arch unless such term or condition is specifically agreed to by Arch in writing signed by a duly authorized officer of Arch. 

3.8 Delivery of Products. Arch shall deliver to Codexis and/or its designee the amount of each of the Product(s) specified in each
Product Purchase Order, together with any other sales documentation or other materials specified in such Purchase Order, no later than the date (or dates) mutually agreed by the Parties therein. All Products shall be (a) delivered to Codexis as
inventory supply; or (b) shipped by Arch by air or as otherwise directed by Codexis to the destination designated in writing by Codexis. The Parties shall cooperate in selecting appropriate carriers, and title and risk of loss shall pass to
Codexis upon delivery by Arch to such carrier(s). Arch shall notify Codexis in writing within five (5) days after shipping any Product in order to allow Codexis to properly invoice its customers. Arch shall ship each order of Product under
appropriate packaging and storage conditions, including, for example, using envirotainers or similar temperature-control equipment for shipments where appropriate. All deliveries will be accompanied by the relevant Certificate of Analysis (CoA), and
a detailed delivery note specifying the identity of the material, the quantity and the lot number(s) and any other documents specified in the applicable Product Purchase Order (including, for example, TSE/BSE certificate and Material Safety Data
Sheet (MSDS)). 
 3.9 Inspection of Product. Upon receipt of each shipment of Product, Codexis and/or the Codexis
Customer, shall test and inspect such Product for compliance with the Product Specification and other documentation as set forth in Section 3.12 or otherwise provided by Codexis to Arch pursuant to Section 3.7 (as applicable) for such
Product corresponding to 
  

 13 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
such shipment. Codexis and/or the Codexis Customer shall inform Arch of the result of the acceptance inspection including the judgment of acceptance or rejection of all or part of a shipment in
writing within ten (10) days (or such other time as may be agreed to by Codexis and a Codexis Customer, as specified in the applicable Product Purchase Order) after the delivery of such shipment of Products. In the event that Arch receives a
written notice of rejection from Codexis and/or the Codexis Customer within the timeframes set forth in the following sentence, subject to Section 3.11, Arch shall replace such rejected Product pursuant to Section 3.10. If Codexis and/or
the Codexis Customer fails to notify Arch of a rejection within the requisite timeframe, the shipment of Products shall be deemed accepted by Codexis and/or the Codexis Customer. Regardless of any rejection of all or part of a shipment of Product,
Codexis shall pay for such Product and if such rejection is determined to be proper by Arch or pursuant to the dispute resolution mechanism set forth in Section 3.11, Codexis shall be entitled to, at its sole discretion, a credit or refund of
such properly rejected Product. 
 3.10 Replacement of Defective Product. In the event that Arch receives a written
notice of rejection from Codexis and/or the Codexis Customer, Arch shall, at the sole cost and expense of Arch, replace any shipment of such rejected Product, including without limitation disposal of such Product, within sixty (60) days after
receiving Codexis’ and/or the Codexis Customer’s written notice of rejection. For clarity, the foregoing right shall not limit any other remedy available at law or in equity. Codexis and/or the Codexis Customer shall keep such defective
Product at the premises of Codexis and/or the Codexis Customer, as applicable, until receipt of Arch’s instruction for Codexis and/or the Codexis Customer to return or otherwise dispose of such defective Product. Notwithstanding anything to the
contrary, (i) Arch shall have no obligation to replace any shipment of Product or part thereof pursuant to this Section 3.10 or issue a refund or credit pursuant to Section 3.9 in the event Arch can establish that the Product is not
defective or such defect occurred after delivery of Product; and (ii) if the basis for any rejection is a defect due to a change in any regulatory requirement as specified by a Government Authority and which change was not identified by the
Government Authority prior to Arch’s manufacture of such Product, then the costs associated with replacement of the defective Product (which costs, for the avoidance of doubt, do not include costs to be borne by Arch in updating its
manufacturing processes and procedures to become compliant with any new regulatory requirement or any other costs not attributable directly to the replacement) shall be borne equally by the Parties. 

3.11 Disputes. If Arch disputes Codexis’ and/or the Codexis Customer’s right to reject all or part of any shipment of
any Product as set forth in Section 3.9, Arch shall notify Codexis within ten (10) days after receipt of Codexis’ and/or the Codexis Customer’s written notice of such rejection. Such dispute shall be resolved by a Third Party
within thirty (30) days of such notice. Such Third Party shall have expertise in the areas of quality control and quality assurance for active pharmaceutical ingredient and intermediate manufacturing, the identity of whom shall be mutually
agreed upon by the Parties, and the appointment of whom shall not be unreasonably delayed or conditioned by either Party. The determination of such Third Party with respect to all or part of any shipment of any Product shall be final and binding
upon the Parties. The Third Party’s scope of review and decision shall be strictly limited to the reasons given by Codexis in rejecting the shipment or part thereof, and such Third Party may not consider any alleged defects or reasons beyond
the alleged defects and reasons given by Codexis. 
  

 14 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
For the avoidance of doubt, if such Third Party determines that the reasons given by Codexis in rejecting the shipment or part thereof were not proper, then no refund or credit shall be due to
Codexis under Section 3.10, even if such Third Party determines that the shipment was defective on other, independent bases. The fees and expenses of such Third Party shall be paid by the Party against which the determination is made.
Notwithstanding anything to the contrary in this Article 3, Arch shall continue delivering Product(s), including without limitation replacement of any defective Products, pursuant to the terms of this Agreement during the dispute resolution process
set forth in this Section 3.11. 
 3.12 Changes and Quality Control. 

3.12.1 Specification. As soon as practicable, but in any event no later than thirty (30) days prior to the First Commercial
Sale of each Product, Codexis shall provide Arch with the specification for such Product (each, a “Product Specification”), as mutually agreed upon by the Parties. All Product supplied by Arch hereunder shall comply with the
applicable Product Specification. 
 3.12.2 Changes. Arch shall not make any changes or alterations in (i) the
Product Specification(s) for any Product or (ii) the process for the manufacture of any Product which change may impact the Product quality (each, a “Change”) without Codexis’ prior written consent. 

(a) In the event that Arch requests a Change and Codexis consents to such Change, Arch shall bear the costs associated with
implementing such Change, including without limitation any costs incurred in connection with testing such Change by Codexis or any Third Party laboratory designated by Codexis. 

(b) In the event that Codexis requests a Change, Codexis shall bear the costs associated with such Change, including without
limitation any costs incurred in connection with testing such Change by any Third Party laboratory. 
 3.12.3 Manufacturing
Standards and Procedures. Unless otherwise agreed in writing by Codexis, all Products supplied hereunder and the manufacture thereof shall comply with appropriate quality standards depending on the intended market, including but not limited to
cGMP. Arch shall adopt and maintain quality assurance procedures and perform quality control tests designed to ensure that all Products manufactured under this Agreement conform to and are manufactured in accordance with this Agreement, including
any other requirements of a Codexis Customer which requirements shall be set forth in the relevant Purchase Order or otherwise set forth in writing by Codexis. Without limiting the foregoing, Arch agrees as follows: 

(a) Arch shall be responsible for creating and retaining all records relating to the manufacturing, analysis and distribution,
testing and release of materials, production and quality control (including in-process controls) as actual manufacturer, including Product Quality Review, generally in accordance with cGMP and shall provide copies to Codexis upon its reasonable
written request. 
  

 15 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 (b) Arch shall retain reference samples from each Batch of Products for the period
of time required by Applicable Law and cGMP regulations. Arch shall retain samples sufficient to conduct at least three re-examinations. Arch shall, upon written request, make reference samples available for inspection, testing, analysis and
examination by Codexis and/or any relevant Government Authority, solely for the purposes of determining compliance with Applicable Law or the requirements under this Agreement. 

(c) The equipment and facilities used for manufacturing must be qualified by Arch. The results must be documented in writing. The
processes for manufacturing of Product must be validated by Arch in accordance with the approved validation protocol. The validation should be performed on the three consecutive Batches which should each be included in formal stability studies. The
stability studies should be performed in accordance to the valid ICH guidelines for the Product. 
 (d) Arch shall
ensure that the Products have been manufactured in compliance with all requirements under this Agreement and shall release only Batches, which have been manufactured and analyzed by Arch according to the Product Specifications. 

3.12.4 Manufacturing and Storage Location. 

(a) Prior to the manufacture of any Product, Arch shall inform Codexis as to which Manufacturing Facility will be used to
manufacture such Product. All such Product shall be manufactured at such Manufacturing Facility, and Arch shall not, without Codexis’ prior written consent, not to be unreasonably withheld, manufacture such Product at any facility other than
such Manufacturing Facility. Notwithstanding the foregoing, in the event that Arch makes a good faith determination that it is more cost-efficient to outsource certain aspects or steps in the manufacturing of Products to Third Parties ( the
“Subcontract Manufacturer”), Arch may, upon Codexis’ prior, written consent (not to be unreasonably withheld), use such Subcontract Manufacturers to manufacture Products provided that (i) such subcontracting does not
increase manufacturing costs, (ii) Arch shall retain title to Products even when and during such time that Products are manufactured, maintained or held at the site of a Subcontract Manufacturer and (iii) Arch shall remain liable for all
action or inaction of any Subcontract Manufacturer and any such action or inaction which would be deemed a breach of this Agreement had such action or inaction been taken by Arch shall be deemed a breach of this Agreement by Arch. 

(b) Prior to the delivery of any such Product to Codexis, all such Product shall be stored in accordance with this Agreement, the
applicable Specifications or as otherwise instructed in writing by Codexis, and at such Manufacturing Facility. Within five (5) days after Codexis’ request, Arch shall provide information relating to such stored Product, including without
limitation the date of manufacture and the amount of such stored Product. 
 3.12.5 Inspections of Manufacturing
Facility. 
 (a) Inspection by Codexis. Representatives of Codexis (i) shall upon Codexis’ request be
permitted to review Arch’s quality assurance/quality control and Environmental, Health and Safety procedures; and (ii) may, during normal business hours and 

 

 16 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
with reasonable advance notice, conduct a supplier audit of the Manufacturing Facility(ies); provided, that unless there is a material change to the operation of the Manufacturing
Facility(ies) (such as introduction of new assets or products), such audit shall not extend beyond two (2) Business Days per facility and, unless deficiencies are discovered during any such audit, shall not be conducted more than once per
calendar year at any particular Manufacturing Facility. Arch shall permit representatives of Codexis to inspect the Manufacturing Facility(ies) to verify that the Products are being manufactured and supplied in accordance with the applicable
Specification, cGMP, the relevant terms of this Agreement and Applicable Law. Arch shall promptly remedy or cause the remedy of any deficiencies that may be noted in any such inspection. 

(b) Inspections by Third Party Customers of Codexis. Representatives of Codexis’ Third Party customers for Products may,
during normal business hours and with reasonable advance notice, conduct a supplier audit of the applicable Manufacturing Facility(ies); provided, that each such audit shall not extend beyond two (2) Business Days per facility and,
unless deficiencies are discovered during any such audit, shall not be conducted more than once by any particular Third Party customer at any particular Manufacturing Facility in a particular calendar year. Arch shall permit such representatives to
inspect the applicable Manufacturing Facility to verify that the Products are being manufactured and supplied in accordance with the applicable Product Specification, cGMP, Environmental, Health and Safety standards and Applicable Law. Arch shall
promptly remedy or cause the remedy of any deficiencies that may be noted in any such inspection. 
 (c) Inspection by
Government Authority. Arch agrees to provide access for Government Authority representatives to its facilities, including without limitation, the Manufacturing Facility(ies), for inspection at any time. Arch shall notify Codexis of any of the
foregoing as soon as possible. Arch shall fully cooperate with any such inspection and, within five (5) days after such inspection, shall provide Codexis with copies of all correspondence to and from any Government Authorities in connection
with any such inspection, including without limitation any formal reports; provided, however, that in the event that any such inspection reveals any deficiency, Arch shall provide such copies within twenty-four (24) hours after
such inspection. 
 3.12.6 Recalls. In the event that (a) either Party determines that an event, incident, or
circumstance has occurred which may result in the need for a recall or other removal of any Product from the market in any country; (b) any Government Authority threatens or initiates any action to remove any Product from the market; or
(c) any Government Authority requires distribution of a “Dear Doctor” letter or its equivalent, regarding use of any Product, each Party, as applicable, shall (i) promptly advise the other Party in writing with respect thereto,
and each Party, as applicable, shall provide to the other Party copies of all relevant correspondence, notices, and the like, and (ii) fully cooperate with the other Party regarding any proposed recall, withdrawal, or field correction.

  

 17 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 4. NON-EXCLUSIVE RELATIONSHIP. 

4.1 Conversion to Non-Exclusive Relationship. On a Product-by-Product basis, the exclusive relationship set forth in Sections 2.1
and 3.1 shall be converted to a Non-Exclusive Relationship in the event of any of the following: 
 (a) Upon written
notice by Codexis to Arch that it is not commercially feasible, in Codexis’ sole discretion, for Codexis to continue to supply any of the respective Codexis Enzyme(s) to Arch pursuant to Article 2, and Codexis provides ninety (90) days
prior notice to Arch of such decision at any time after the second anniversary of the Effective Date, on a Product-by-Product basis. 

(b) Upon written notice by Codexis to Arch if Arch fails to file a Drug Master File for each of [*] in the U.S. within
eighteen (18) months after the Effective Date, in which case [*], as applicable, shall be subject to a Non-Exclusive Relationship; provided, however that if Arch’s failure to file the DMF within the requisite time period is due to a
change in a regulatory requirement imposed by a Government Authority, including but not limited to a requirement to specify a new impurity that had not previously been required, then Codexis and Arch shall engage in good faith discussions regarding
an extension of the requisite time period set forth in this subsection (b) but any such extension shall only be upon mutual agreement of the Parties; and/or 

(c) Upon written notice by either Party to the other Party upon a material, uncured breach by the other Party that is not cured
within thirty (30) days’ written notice of such breach, in which case any or all Products, as identified by the non-breaching Party, shall be subject to a Non-Exclusive Relationship. 

4.2 “Non-Exclusive Relationship” shall mean, for the relevant Product, notwithstanding Sections 2.1 and 3.1,
(i) Codexis shall have the right to purchase the Product from any Third Party and also the right to sell/license the Codexis Enzymes and Codexis Processes to any Third Party; (ii) Arch shall have a corresponding right to sell the Product
to any Third Party and also the right to procure the enzymes (other than Codexis Enzymes) and processes (other than the Codexis Process) needed to manufacture such Product from any Third Party; and (iii) without prejudice to above, with respect
to a right granted by one Party to the other Party under this Agreement, such right may be granted to any Third Party in the first Party’s sole discretion. For the avoidance of doubt, the establishment of a Non-Exclusive Relationship in respect
of any Product shall not affect the rights and obligations in respect of any other Products. 
 5. PRODUCT DEVELOPMENT 

5.1 Arch Development Responsibilities. On a Product-by-Product basis, Arch shall be solely responsible for and shall
(i) scale-up and implement the Codexis Process(es), (ii) develop the Non-Codexis Process(es), and (iii) develop and manufacture the Product(s) in accordance with this Agreement. Such development shall include without limitation,
chemistry development, scale-up, and obtaining any and all regulatory approvals and licenses required for such development and/or commercialization. Arch shall solely be responsible for all costs

  

 18 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
associated with its development activities under this Section 5.1, including without limitation, developing all required manufacturing and release testing for the Product(s). 

5.2 Codexis Development Responsibilities. On a Product-by-Product basis, Codexis and/or its Affiliates shall be responsible for
(a) selection of the manufacturing route for each Product in consultation with Arch; and (b) development of Codexis Enzyme(s) and the respective Codexis Process(es) for use in the manufacture of each Product. Notwithstanding the foregoing,
Codexis, in its sole discretion, shall identify Codexis Enzyme(s) for use in the manufacture of Product(s). Codexis shall be responsible for all costs associated with its development activities under this Section 5.2, including without
limitation, appropriate analytical methods for release testing of Codexis Enzyme(s). 
 5.3 Development Reports by Arch.
On a Product-by-Product basis, as of the Effective Date, Arch shall provide Codexis with a written report, twice per calendar year within ten (10) Business Days after June 30 and December 31 of each such calendar year, on the status
of its activities regarding the development of Non-Codexis Process(es) as set forth in Section 5.1 with respect to any Products, including without limitation, any Arch Improvements and any improvements made to the then-current Non-Codexis
Process(es), in technical detail, made during the period covered by such report. 
 5.4 Inventory
Transaction Reports; Audits. Arch shall maintain adequate records with respect to inventory of Products and each Codexis Enzyme, which records shall include without limitation information specifying how such Codexis Enzyme is used, stored,
transferred, or otherwise disposed. On a Product-by-Product basis and Codexis Enzyme-by-Codexis Enzyme basis, following the first delivery of such Codexis Enzyme to Arch, Arch shall deliver to Codexis on a semi-monthly (or twice per month) basis, on
or around the 15th day of each month and within two
(2) Business Days after the end of each month, a written report setting forth in sufficient detail the information set forth Exhibit 5.4, and a report regarding the loading, scrap and utilization information of each such Codexis Enzyme,
in each case for the period covered by such report. Codexis shall have the right to, at Codexis’ expense, visit (or have a representative visit) Arch’s Manufacturing Facilities twice per month for purposes of collecting data regarding
sales of Products and/or inventory of Codexis Enzymes and/or inventory of Products. Such visits shall be on or around the
15th day each month and the last day of each month.
Without limiting the foregoing, if Arch uses at least ten percent (10%) more Codexis Enzyme than planned, Arch shall promptly notify Codexis’ Vice President of Operations via email of such additional use and the reasons for such use and,
for the avoidance of doubt, such additional use shall also be noted on the applicable report submitted pursuant to this Section 5.4. 

5.5 Payables/Receivables. The Parties shall, within three (3) Business Days after the end of each calendar month, agree
upon a written report of any payable/receivable amounts in respect of the prior month’s activities in respect of Codexis Enzymes, Products or any other work under this Agreement or any other agreements between the Parties (or their
Affiliates) entered into contemporaneously with this Agreement. 
  

 19 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 6. MARKETING OF PRODUCTS 

6.1 Diligence by the Parties. Codexis shall use commercially reasonable efforts to market and sell Products to Codexis Customers.
Arch shall use commercially reasonable efforts to market and sell Products to Arch Customers. 
 6.2 Prices and Terms of
Sale. Codexis shall decide, in its sole discretion, the selling price of Products to be sold to Codexis Customers. Arch shall decide, in its sole discretion, the selling price of Products to be sold to Arch Customers 

6.3 Product Orders. In the event that (i) Arch identifies any companies for any Product that fall within Codexis Customers,
Arch shall direct such companies to submit inquires for such Product to Codexis; and (ii) Codexis identifies any potential companies for any Product in that fall within Arch Customers, Codexis shall direct such companies to submit inquiries for
such Product to Arch. 
 6.4 Weekly Sales Reporting by Arch. On a weekly basis, Arch shall
deliver to Codexis a written report summarizing Product sales made by Arch during such week. Such report shall be delivered to Codexis electronically (via e-mail, pdf or other electronic means) on a weekly basis and delivered to Codexis or its
representative during the visits referenced in Section 5.4 on or around the
15th and end of each month. 

7. REGULATORY FILINGS AND COMPLIANCE 

7.1 Arch’s Regulatory Responsibilities. Arch shall be solely responsible for and shall carry out and complete all regulatory
updates and filings necessary to obtain the consent of any Government Authorities (including without limitation the FDA) to the extent required in order to ensure that Arch and/or Codexis’ use of any Codexis Enzymes and/or Codexis Processes to
manufacture, have manufactured, use, sell, offer for sale, import, export, and/or otherwise distribute Products for use in a drug product to be marketed in India complies with all Applicable Law and such updates and filings shall be in Arch’s
name and owned exclusively by Arch. Arch shall also be responsible for filing a Drug Master File for each of [*] in the U.S. and Europe. In addition, in the event that a Codexis Customer requires such updates and filings, the obligations of
Arch under this Section 7.1 shall also apply for the territory in which Product is to be sold to such Codexis Customer, as designated by such Codexis Customer or by Codexis, for and on behalf of such Codexis Customer. Arch shall designate as
confidential in any such regulatory filings any Confidential Information of Codexis contained therein, and Arch shall make requests under Applicable Law for confidential treatment covering such Confidential Information. Arch shall, in its sole
discretion, determine any matters regarding the regulatory strategy of Product(s) to be sold to Arch Customers.  

7.2 Codexis’ Regulatory Responsibilities. Codexis will provide to Arch (a) all documentation Controlled by Codexis
and/or its Affiliates requested by the relevant Government Authorities necessary for approvals; and (b) all reasonable assistance as requested by Arch, in order to permit Arch and/or its Affiliates to (i) make the filings contemplated in
Section 7.1 and (ii) register with and obtain authorizations from such Government Authorities to use each Codexis Enzyme and Codexis Process to manufacture and market Product(s) to Codexis

  

 20 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
Customers. In particular, Codexis shall provide Arch with all the documents and information required for registrations, at health authorities and for GMO registration, if required under
Applicable Law, including without limitation the full description of stability data, toxicological data, certificates of analysis and material safety data sheets, in each case, solely to the extent applicable to the applicable Codexis Enzyme used in
each Codexis Process. 
 7.2.1 Regulatory Reports. Arch shall notify Codexis within a commercially reasonable period of
time of any regulatory filing, or license application related to the manufacture, use, sale, import, export and/or other distribution of any Product during the Term. 

8. TRADEMARK LICENSE 

8.1 Trademark License Grants. Codexis hereby grants to Arch, upon the terms and subject to the conditions and restrictions of this
Agreement, including without limitation Section 8.2, a non-exclusive, non-transferable right and license to use the Codexis Trademarks, upon and solely in connection with the distribution of Products to be sold to (x) Codexis Customers and
(y) Codexis India. Arch accepts and acknowledges that the Codexis Trademarks are valuable assets of Codexis and agrees to use utmost care in ensuring that its use of the Codexis Trademarks is in strict compliance with the terms and conditions
of this Agreement. Arch shall have no right to use Codexis Trademarks in connection with any Products distributed to Arch Customers (other than Codexis India) except as otherwise authorized in writing by Codexis and, for the avoidance of doubt,
Products sold to Arch Customers (other than Codexis India) shall bear Arch Trademarks. 
 8.2 Restrictions on Use.

 8.2.1 Arch shall not (a) change or modify the Codexis Trademarks, or create any design variation of the
Codexis Trademarks, except to the extent required by law applicable to packaging materials and reasonably satisfactory to Codexis; (b) join any name, mark or logo with the Codexis Trademarks so as to form a composite trade name or trademark;
(c) use the Codexis Trademarks in any manner that reflects adversely upon the Codexis Trademarks or Codexis or its Affiliates; (d) register, seek to register, or use any other trademark that is confusingly similar to or dilutes the Codexis
Trademarks; (e) challenge the validity or enforceability of any of the Codexis Trademarks or Codexis’ right to grant the license to the Codexis Trademarks set forth herein; or (f) use the Codexis Trademarks in any manner inconsistent
with the express rights granted to Arch hereunder. All use of the Codexis Trademarks made by Arch hereunder shall faithfully reproduce the design and appearance of the Codexis Trademarks and adhere to any standards provided by Codexis to Arch in
writing from time to time. 
 8.2.2 To the extent allowed by Applicable Law and consistent with Codexis internal
trademark policy as to size, location and prominence, all labeling of any Product, including without limitation packaging and package inserts and any promotional materials associated with such Product shall carry, in a conspicuous location, the
Codexis Trademarks, subject to Codexis’ reasonable approval of the size, position, and location thereof on the Product or its components. Codexis reserves the right to provide Arch with adhesive labels, stickers or markers which reproduce the
Codexis Trademarks, and Arch shall use such labels, stickers or 
  

 21 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
markers in accordance with any standards provided by Codexis to Arch in writing from time to time. 

8.3 Quality Control. To control and monitor compliance with the trademark licenses provided in this Article 8, each Party or its
duly authorized representative shall have the right, at any time upon reasonable written notice to the other Party, to inspect, test and audit samples of (a) Products and packaging therefor bearing the Codexis Trademarks or the Arch Trademarks,
as applicable; (b) all advertising, promotional and marketing materials bearing the Codexis Trademarks or the Arch Trademarks, as applicable; and (c) any other uses of the Codexis Trademarks or the Arch Trademarks, as applicable, by Arch
or Codexis and/or its Affiliates, respectively; Arch and Codexis and/or its Affiliates shall promptly remedy any non-compliant uses of the Codexis Trademarks or the Arch Trademarks, respectively; provided, that in the event either Party
reasonably determines that any such non-compliant uses poses immediate threat to the validity or enforceability of its trademarks, the other Party shall, upon written notice from such Party, immediately cease and desist all such non-conforming uses.
Without limiting any of the foregoing, Arch shall submit samples of Products and packaging therefor, and advertising, promotional and marketing materials bearing the Codexis Trademarks to Codexis no less than once at the end of each calendar year
during the Term for testing and review by Codexis. 
 8.4 No Other Rights. 

8.4.1 Except as expressly provided otherwise in this Agreement, including in Article 2, no right, title, or interest is granted by
Codexis and/or its Affiliates to Arch and its Affiliates in, to, or under any intellectual property rights Controlled by Codexis and/or its Affiliates, including without limitation, the Codexis IP Rights. 

8.4.2 Except as expressly provided otherwise in this Agreement, including in Article 3 or Section 11.1.2 , no right, title,
or interest is granted by Arch to Codexis in, to, or under any intellectual property rights Controlled by Arch. 
 9. PAYMENTS

 9.1 Product Sales by Parties. 

9.1.1 Codexis shall pay Arch a transfer price in respect of each Product sold to Codexis by Arch as agreed to in writing by the
Parties. 
 9.1.2 Arch shall pay Codexis a license royalty in respect of each Product sold by Arch to an Arch Customer,
as agreed to in writing by the Parties. 
 9.2 Enzyme Supply by Codexis. 

9.2.1 On a Codexis Enzyme-by-Codexis Enzyme basis, Arch shall pay to Codexis [*] per kilogram of Codexis Enzyme or such
other amount as may be agreed to in writing by the Parties. 
  

 22 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 9.2.2 Arch shall pay Codexis within ninety (90) days of delivery of each
shipment of Codexis Enzyme hereunder. All payments made by Arch to Codexis for Codexis Enzymes shall be free of offsets, deductions, or withholdings of any kind for any and all taxes, duties, or other similar fees and/or penalties levied by any
Government Authority, which taxes, duties, fees and/or penalties, if any, shall be borne solely by Arch. Notwithstanding, if any order of any income tax authority specifies deduction of tax at source on account of income tax payable by Codexis, the
amount computed at the rate specified in the said order shall be withheld and deposited in government account as per Applicable Law. 

9.3 Late Payment Interest. Any payment under the terms and conditions of this Agreement made after the date such payment is due
and payable shall bear interest as of the day after the date such payment was due and payable and shall continue to accrue such interest until such payment is made at a rate equal to the lesser of either (a) two percent (2%) above the
prime rate as reported by Federal Reserve Bank of New York, located in New York, New York, as of the date such payment was due and payable, or (b) the maximum rate permitted by Applicable Law. 

10. CONFIDENTIALITY 

10.1 In General. In connection with this Agreement each Party (the “Disclosing Party”) may provide to the other
Party (the “Receiving Party”), Confidential Information. 
 10.2 Non-Disclosure and Non-Use. The
Receiving Party shall maintain the Confidential Information of the Disclosing Party in confidence, shall not disclose such Confidential Information to any Third Party, and shall not use such Confidential Information for any purpose except as
expressly permitted under the terms and conditions of this Agreement. Notwithstanding the previous sentence, the Receiving Party may disclose the Confidential Information of the Disclosing Party solely on a “need to know basis” to its
Affiliates and its officers, directors, employees, legal counsel, contractors and agents, and independent legal counsel, each of whom prior to disclosure must be bound by obligations of nondisclosure and non-use no less restrictive than the
obligations set forth in this Article 10; provided, however, that, in each of the above situations, the Receiving Party shall remain responsible for any failure by any person or entity who receives Confidential Information pursuant to
this Section 10.2 to treat such Confidential Information as required under this Article 10. The Receiving Party shall take the same degree of care that the Receiving Party uses to protect its own confidential and proprietary information of a
similar nature and importance, but in no event shall such care be less than reasonable care. 
 10.3 Exceptions. The
obligations of non-disclosure and non-use under Section 10.2 will not apply as to particular Confidential Information of a Disclosing Party to the extent that such Confidential Information: (a) is at the time of receipt, or thereafter
becomes, through no fault of the Receiving Party or its Affiliates, published or publicly known or available; (b) is known by the Receiving Party or its Affiliates at the time of receiving such information, as evidenced by competent written
records; (c) is hereafter furnished to the Receiving Party or its Affiliates by a Third Party without breach of a duty to the Disclosing Party; or (d) is independently discovered or developed by the Receiving Party or its Affiliates
without use of, 
  

 23 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
application of, access to, or reference to Confidential Information of the Disclosing Party, as evidenced by competent written records. 

10.4 Disclosure Required by Law. Disclosure of Confidential Information shall not be precluded if such disclosure (a) is in
response to a valid order, or required under the regulations, of a court or other governmental body; or (b) is required by Applicable Law; provided, however, that the Receiving Party first has given reasonable prior notice to the
Disclosing Party and at the Disclosing Party’s request, the Receiving Party cooperates with the Disclosing Party’s efforts, as applicable, to obtain a protective order limiting the extent of such disclosure and requiring that the
Confidential Information so disclosed be used only for the purposes for which such order was issued or as required by such Applicable Law. 

10.5 Remedies. The Receiving Party agrees that its obligations under this Article 10 are necessary and reasonable to protect the
Disclosing Party’s business interests and that the unauthorized disclosure or use of Confidential Information of the Disclosing Party will cause irreparable harm and significant injury, the degree of which may be difficult to ascertain. The
Receiving Party further acknowledges and agrees that in the event of any actual or threatened breach of this Article 10, the Disclosing Party may have no adequate remedy at law and, accordingly, that the Disclosing Party will have the right to seek
an immediate injunction, without an obligation to post a bond or any similar security, enjoining any breach or threatened breach of this Article 10, as well as the right to pursue any and all other rights and remedies available at law or in equity
for such breach or threatened breach. 
 10.6 Agreement Terms. The existence of, and the terms and conditions of, this
Agreement shall be Confidential Information of each of the Parties, and subject to the terms of this Article 10; provided, however, that (x) each Party may disclose this Agreement, in confidence, (i) to legal, scientific and financial
advisors and (ii) in connection with any proposed legal transaction involving the disclosing Party in the form of mergers, offerings, acquisitions, fundings and investments; and (y) each Party may disclose this Agreement, in its entirety
or with portions redacted, as may be required by Applicable Law, including but not limited to filing of this Agreement with the Securities and Exchange Commission (and, for the avoidance of doubt, if any such disclosure or filing is made on a
non-confidential basis then the portions disclosed or filed shall no longer be deemed Confidential Information). 
 10.7
Survival. All obligations of non-disclosure and non-use imposed pursuant to the terms and conditions of this Article 10 shall survive expiration or termination of this Agreement and continue in full force and effect for a period of ten
(10) years after the effective date of such expiration or such termination. 
 11. INTELLECTUAL PROPERTY 

11.1 Ownership by Codexis. 

11.1.1 As between the Parties, subject only to the licenses set forth in Articles 2 or 8, Codexis shall retain all right, title and
interest in, to and under the Codexis IP Rights, Codexis Trademarks, Codexis Process, each and every Codexis Enzyme, and Codexis Improvements. 
  

 24 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 11.1.2 Arch hereby assigns to Codexis all its right, title, and interest in, to, and
under any and all discovery, invention, contribution, method, finding, or improvement, whether or not patentable, and all related intellectual property, including without limitation Patents and know-how, that is conceived, reduced to practice, or
otherwise developed by Arch or an Affiliate of Arch, either solely or jointly with Codexis and/or a Third Party, during the Term that relates to the Codexis IP Rights, Codexis Trademarks, Codexis Process, any Codexis Enzyme, and/or the Codexis
Improvements (collectively, the “Arch Bio-Chemical Improvements”). Arch and its Affiliates agree to cooperate with Codexis, at Codexis’ reasonable request and expense, in the preparation of any patent application claiming any
subject matter within such inventions and intellectual property rights. 
 11.1.3 Codexis, at its own expense, shall have
the sole right, but not the obligation, to file applications for and to control the prosecution and maintenance of the Codexis IP Rights and Codexis Trademarks, including without limitation any and all intellectual property assigned by Arch to
Codexis pursuant to Section 11.1.2 , except as otherwise expressly noted. 
 11.2 Ownership by Arch. 

11.2.1 As between the Parties, subject only to the licenses set forth in Articles 3 or 8, Arch shall retain all right, title and
interest in, to and under the Arch Chemical Improvements and Arch Trademarks. 
 11.2.2 Arch, at its own expense, shall
have the sole right, but not the obligation, to file applications for and to control the prosecution and maintenance of the intellectual property rights embodied in the Non-Codexis Process, Arch Chemical Improvements and Arch Trademarks. 

11.3 Enforcement. 

11.3.1 At any time during the Term, if a Party determines that a Third Party is or may be infringing any Patent, or may have
misappropriated any other right, within the Codexis IP Rights, the Party making such determination shall promptly provide written notice to the other Party thereof. 

11.3.2 Codexis, at its expense, shall have the right, but not the obligation, to enforce all rights (a) in the Codexis
Enzyme(s), Codexis Process(es), and/or Codexis Improvements and any and all intellectual property rights therein, including without limitation the Codexis IP Rights; and (b) with respect to any and all intellectual property assigned by Arch to
Codexis pursuant to Section 11.1.2. 
 11.3.3 In the event that Codexis enforces its rights pursuant to this
Section 11.3, Arch and its Affiliates, if applicable, shall cooperate fully with Codexis in such enforcement, including without limitation, by joining as a party plaintiff and executing such documents as Codexis may reasonably request.

 11.4 Attorney in Fact. If Codexis cannot obtain the signature of Arch or its Affiliates, as applicable, on any
document necessary to exercise its rights under this Article 11, Arch and 
  

 25 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
each of its Affiliates hereby irrevocably designates and appoints Codexis and each of its duly authorized officers and agents as Arch’s agent and attorney-in-fact, to act for, and on behalf
of Arch, to execute and file any such document to further exercise Codexis’ rights or protections with the same force and effect as if executed and delivered by Arch or its Affiliates. Exercise of the foregoing right shall be at the sole
expense of Codexis, and Codexis agrees to hold Arch and each of its Affiliates harmless against any loss, liability, or expense that Arch may have to incur on account of the exercise by Codexis of such right. This Section 11.4 shall not apply
with respect to the execution and/or filing of any document in the event of any dispute between the Parties with respect to the ownership provision under Section 11.1.2 . If any document is executed and/or filed by Codexis on behalf of Arch
prior to any dispute between the two Parties on any matter contained in Section 11.1, such document shall not bind Arch in any manner. On each occasion of exercise of the right conferred in the first sentence of this Section 11.4, Codexis
agrees to provide a written notice to Arch within seven (7) days after such exercise, containing material particulars of the document filed and/or executed. 

11.5 Allocation of Recovery. Any recovery awarded by a court of competent jurisdiction or final resort in an unreversed,
unappealed, or unappealable decision or judgment from an action by Codexis to enforce any rights within the Codexis IP Rights, including without limitation any and all intellectual property assigned by Arch to Codexis pursuant to Section 11.1.2
, shall be first applied to reimburse Codexis’ and Arch’s unreimbursed expenses on pro-rata basis in proportion to their expenses, including without limitation reasonable attorney’s fees and court costs. Any remaining amount of such
damages or other monetary awards shall then be applied between the Parties in such action or proceeding on a pro rata basis based upon the Parties’ respective out-of-pocket expenses directly associated with such action or proceeding. 

 11.6 Termination for Patent Challenge. If Arch or any of its Affiliates challenges in a court of competent
jurisdiction or in any interference, re-examination or opposition proceeding, the validity, scope or enforceability of any Patent embodied in the Codexis Enzyme(s), Codexis Process(es), and/or Codexis Improvements, including without limitation the
Codexis IP Rights, Codexis shall have the right to terminate this Agreement immediately upon written notice to Arch provided in accordance with Section 16.7. If Applicable Law prevents Codexis from termination of this Agreement pursuant to this
Section 11.6, Arch acknowledges and agrees that Arch may retain the licenses granted under this Agreement; provided, however, that the payments agreed upon per Section 9.1.2 shall be tripled. 

11.7 Third Party Claims. If, after the Effective Date, Arch becomes aware of any claims made by Third Parties that such Third
Party’s intellectual property may be infringed by the use, manufacture, having manufactured, marketing, selling, offering to sell, importing, exporting, and/or other distribution of any Products, Arch shall promptly notify Codexis thereof. If,
after the Effective Date, Codexis becomes aware of any claims made by Third Parties that such Third Party’s intellectual property rights may be infringed by the use, manufacture, having manufactured, marketing, selling, offering to sell,
importing, exporting, and/or other distribution of any Codexis Enzymes or Codexis Process, Codexis shall promptly notify Arch thereof. The Parties shall meet and discuss in good faith steps to avoid any such potential infringement, including without
limitation whether to obtain rights to practice under such Third Party-
  

 26 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
intellectual property, and, if so, which Party shall obtain such rights and the terms of obtaining such rights and the relative sharing of the costs thereof. 

12. REPRESENTATIONS, WARRANTIES AND COVENANTS 

12.1 Representations and Warranties of Codexis. Codexis hereby represents and warrants to Arch that as of the Effective Date:

 12.1.1 Codexis is a corporation organized under the laws of Delaware and is authorized to do business to the extent
necessary to fulfill its obligations hereunder; 
 12.1.2 Codexis has the full right and authority to enter into this
Agreement, and no consent or authorization not obtained prior to the Effective Date is necessary to be obtained; 
 12.1.3
Codexis has obtained all licenses, authorizations, and permissions necessary under Applicable Law for meeting and performing its obligations under this Agreement and all such licenses, authorizations, and permissions are in full force and
effect; 
 12.1.4 Codexis Controls the Codexis IP Rights; 

12.1.5 Codexis has not granted any right, license, or interest in, to, or under the Codexis IP Rights that is inconsistent with
the rights granted to Arch hereunder; 
 12.1.6 to the knowledge of Codexis, there is no material impediment that would
prevent, preclude, or otherwise inhibit its ability to grant the rights and licenses granted, or to perform its obligations, under this Agreement; 

12.1.7 Codexis is not a party to any agreement that would prevent it from granting the rights granted to Arch under this Agreement
or performing its obligations under this Agreement, and the execution, delivery, and performance of this Agreement shall not violate, conflict with, or constitute a default under any agreement (including without limitation its corporate charter or
other organizational documents) to which it is a party or to which it may be bound, or to its knowledge any Applicable Laws or order of any court or other tribunal; and 

12.1.8 Codexis has not entered into any understanding, agreement or amendment to any agreement or granted any right to any Third
Party that would conflict with the terms of this Agreement or the rights granted to Arch hereunder. 
 12.2 Representations
and Warranties of Arch. Arch hereby represents and warrants to Codexis that as of the Effective Date: 
 12.2.1 Arch
is a corporation organized under the laws of India and is authorized to do business to the extent necessary to fulfill its obligations hereunder; 

12.2.2 Arch has the full right and authority to enter into this Agreement, and no consent or authorization not obtained prior to
the Effective Date is necessary to be obtained; 
  

 27 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 12.2.3 Arch has obtained all licenses, authorizations, and permissions necessary
under Applicable Law for meeting and performing its obligations under this Agreement and all such licenses, authorizations, and permissions are in full force and effect; 

12.2.4 to the knowledge of Arch, there is no material impediment that would prevent, preclude, or otherwise inhibit its ability to
grant the rights and licenses granted, or to perform its obligations, under this Agreement; 
 12.2.5 Arch is not a party
to any agreement that would prevent it from granting the rights granted to Codexis under this Agreement or performing its obligations under this Agreement, and the execution, delivery, and performance of this Agreement shall not violate, conflict
with, or constitute a default under any agreement (including without limitation its corporate charter or other organizational documents) to which it is a party or to which it may be bound, or to its knowledge any Applicable Laws or order of any
court or other tribunal; 
 12.2.6 Arch’s and its Affiliates’ Manufacturing Facilities and all manufacturing
facilities utilized by Arch or its Affiliates (a) are registered with the appropriate Government Authorities and (b) in compliance with all applicable Government Authority standards and Applicable Law; and 

12.3 Covenants of Codexis. Codexis hereby covenants that: 

12.3.1 Codexis shall keep all licenses, authorizations, and permissions necessary under Applicable Law for the meeting and
performing of its obligations under this Agreement in full force and effect during the Term; 
 12.3.2 except as
otherwise permitted under this Agreement including without limitation Sections 4.1, 4.2 and 2.2, Codexis shall not (i) buy or source any Product from any Third Party and shall not make any purchase commitments with respect to such Products to
any such Third Party, and (ii) on a Product-by-Product basis, sell any Product to any Arch Customer; 
 12.3.3
Codexis shall at all times strictly comply with all Applicable Laws from time to time in force including, without prejudice to the generality of the foregoing, the provisions of the Foreign Corrupt Practices Act of 1977, as amended, and rules
and regulations relating to due and proper performance of its duties and obligations under this Agreement; 
 12.3.4 each
of the Codexis Enzymes shall conform to the applicable Enzyme Specification therefor and be manufactured and supplied in accordance with Applicable Law and be certified to be TSE/BSE free; 

12.3.5 Codexis shall be solely responsible for its own taxes; and 

12.3.6 Codexis shall not during the Term enter into any understanding, agreement or amendment to any agreement or grant any right
to any Third Party that would conflict with the terms of this Agreement or the rights granted to Arch hereunder. 
 12.4
Covenants of Arch. Arch hereby covenants that: 
  

 28 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 12.4.1 Arch shall use Codexis Enzyme(s), Codexis Process(es) and/or Codexis
Improvements solely for the purpose of manufacture of the applicable Product(s) in India pursuant to this Agreement; 

12.4.2 Arch shall not (i) reverse engineer, deconstruct or in any way determine, or attempt to reverse engineer, deconstruct
or in any way determine, the structure or composition of any Codexis Enzyme; or (ii) modify or otherwise create any derivative of any such Codexis Enzyme; or (iii) supply and/or license any Codexis Enzyme to any Third Party; or
(iv) do indirectly, either through a Third Party or an Affiliate, or permit a Third Party or an Affiliate to do any of the activities contained in (i) or (ii) above that Arch itself agrees not to do, unless Arch exercises its option
pursuant to Section 4.1(a); 
 12.4.3 Arch shall protect and maintain the confidential and proprietary nature of
Codexis Enzymes, Codexis Processes, Codexis Improvements and Codexis IP Rights and will take measures and precautions to secure the Codexis IP Rights, Codexis Improvements, Codexis Processes, and each Codexis Enzyme in its exclusive custody and
control against any loss, damage, misuse and/or theft; 
 12.4.4 Arch shall implement the Codexis Process for the
manufacture of Product at the Manufacturing Facility; 
 12.4.5 Arch shall keep all licenses, authorizations, and
permissions necessary under Applicable Law for the meeting and performing of its obligations under this Agreement in full force and effect during the Term; 

12.4.6 Arch shall at all times strictly comply with all Applicable Laws from time to time in force including, without prejudice to
the generality of the foregoing, the provisions of the Drugs & Cosmetic Act 1940, prevailing Drugs Price Control Order, Central Excises Act 1944, The Industries (Development & Regulation) Act, 1951, labour welfare legislation and
the rules, regulations and notifications made or issued thereunder, and import and/or export laws, rules and regulations relating to due and proper performance of its duties and obligations under this Agreement; 

12.4.7 Each of the Products shall (a) conform to the applicable Product Specification therefor; (b) be free of defects
in materials or workmanship under normal use and service and be fit for the purpose for which such Product is intended; (c) not be adulterated or misbranded within the meaning of the U.S. Food, Drug and Cosmetic Act; (d) be certified to be
TSE/BSE free; and (e) be manufactured and supplied in accordance with Applicable Law, including, for example, cGMP, if applicable; 

12.4.8 Arch shall not, on a Product-by-Product basis, sell any Product to any Codexis Customer and shall not make any acceptance
or delivery commitments to any such Codexis Customer; 
 12.4.9 Arch shall use the Codexis Trademarks in strict
compliance with the terms and conditions set forth in Section 8.1; 
  

 29 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 12.4.10 the packaging for all Product shipped by Arch shall bear the Codexis
Trademarks in accordance with Section 8.1; 
 12.4.11 as long as Arch or its successor is manufacturing any Product,
each Manufacturing Facility will be registered with the appropriate Government Authorities and in compliance with all applicable Government Authority standards and Applicable Law; 

12.4.12 Arch shall use packaging for each of the Products, including without limitation, cartons, ship cases, and pallets, of
industry standard strength in order to maintain the quality of such Product during normal transportation and storage; 

12.4.13 Arch shall be solely responsible for its own taxes; and 

12.4.14 Arch shall not during the Term enter into any understanding, agreement or amendment to any agreement or grant any right to
any Third Party that would conflict with the terms of this Agreement or the rights granted to Codexis hereunder. 
 12.5
Limitation of Warranties. EXCEPT AS SPECIFICALLY SET FORTH IN THIS ARTICLE 12, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY, ANY WARRANTY OF
FITNESS FOR A PARTICULAR PURPOSE OR USE, ANY WARRANTY OF NON-INFRINGEMENT, OR ANY OTHER STATUTORY WARRANTY. EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL IMPLIED WARRANTIES. 

13. INDEMNIFICATION AND INSURANCE 

13.1 Arch Indemnification. Arch shall indemnify, defend, and hold Codexis and its directors, officers, employees, agents, and
Affiliates, harmless from and against all Third Party claims, demands, damages, liabilities, losses, costs, and expenses, including without limitation attorney’s fees (each, a “Claim”) resulting from or arising out of
(a) any breach by Arch of any of Arch’s representations, warranties, or covenants under Article 12; (b) the use, storage, handling, transportation, distribution, or any other disposition of any Codexis Enzyme (while under the
exclusive custody or control of Arch or any Affiliate of Arch) by Arch or any Affiliate of Arch; or (c) the development, testing, manufacture, use, exportation, storage, handling, transportation, sale, marketing, distribution, or any other
disposition of any Product (while under the exclusive custody or control of Arch or any Affiliate of Arch) by Arch or any Affiliate of Arch; provided, however, that Arch’s indemnification obligations under this Section 13.1
shall not apply (i) to any such Claim arising out of Codexis’ negligence or willful misconduct; (ii) to the extent such Claim is the responsibility of Codexis under Section 13.2; or (iii) to the extent that Arch has complied
with all Applicable Laws and its rights and obligations under this Agreement. 
 13.2 Codexis Indemnification. Codexis
shall indemnify, defend, and hold Arch, and its directors, officers, employees, agents, and Affiliates, harmless from and against all Third Party claims, demands, damages, liabilities, losses, costs, and expenses, including without limitation
attorney’s fees (each, a “Claim”) resulting from or arising out of (a) any breach by 
  

 30 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
Codexis of any of Codexis’ representations, warranties, or covenants under Article 12; or (b) the development, testing, manufacture, use, sale, offer for sale, importation, exportation,
storage, handling, transportation, distribution, or any other disposition of any Codexis Enzyme (while under the exclusive custody or control of Codexis or any Affiliate of Codexis) by Codexis or any Affiliate of Codexis; provided,
however, that Codexis’ indemnification obligations under this Section 13.2 shall not apply (i) to any such Claim arising out of Arch’s negligence or willful misconduct; (ii) to the extent such Claim is the
responsibility of Arch under Section 13.1; or (iii) to the extent that Codexis has complied with all Applicable Laws and its rights and obligations under this Agreement. 

13.3 Procedure. For purposes of this Article 13, the indemnified Party shall give prompt written notice in accordance with
Section 16.7 to the indemnifying Party of any suits, claims, or demands by Third Parties or the indemnified Party that may give rise to any Claim for which indemnification may be required under this Article 13; provided, however,
that failure to give such notice shall not relieve the indemnifying Party of its obligation to provide indemnification hereunder except if and to the extent that such failure materially affects the ability of the indemnifying Party to defend the
applicable suit, claim, or demand. The indemnifying Party shall be entitled to assume the defense and control of any such suit, claim, or demand of any Third Party at its own cost and expense; provided, however, that the indemnified
Party shall have the right to be represented by its own counsel at its own cost in such matters. In the event that the indemnifying Party declines to or fails to timely assume control of any such suit, claim, or demand, the indemnified Party shall
be entitled to assume such control, conduct the defense of, and settle such suit, claim, or action, all at the sole cost and expense of the indemnifying Party. Neither the indemnifying Party nor the indemnified Party shall settle or dispose of any
such matter in any manner that would adversely affect the rights or interests of the other Party without the prior written consent of the other Party, which shall not be unreasonably withheld or delayed. Each Party shall cooperate with the other
Party and its counsel in the course of the defense of any such suit, claim, or demand, such cooperation to include, without limitation, using reasonable efforts to provide or make available documents, information, and witnesses. 

13.4 Insurance. 

13.4.1 During the Term, each Party shall maintain, at its sole cost and expense, the types of insurance with minimum limits as set
forth in the applicable table in Exhibit 13.4.1. Notwithstanding anything to the contrary in Exhibit 13.4.1, each Party shall be required to maintain product liability insurance with at least the following limits:
(a) any limit mutually agreed to by the Parties, (b) any limit required by a customer that requests to purchase at least Three Million Dollars ($3,000,000) worth of Products collectively from the Parties and their Affiliates in any one
(1) year period, or (c) at the point at which Parties and their Affiliates collectively have sold an aggregate amount of at least Thirty Million Dollars ($30,000,000) worth of Products in any one (1) year period, a combined single
limit of not less than Ten Million Dollars ($10,000,000) per occurrence and in the aggregate. 
 13.4.2 Such insurance
shall insure against all liability arising out of the manufacture, use, sale, distribution, or marketing of Products. The insurance will contain no 

 

 31 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
more than an ordinary deductible. Such insurance shall be primary, without regard to any other insurance the insured Party or any other additional insured shall maintain or otherwise have in
force. The Parties acknowledge and agree that such insurance shall not be construed to create a limit of either Party’s liability with respect to its indemnification obligations under this Section 13.4. In the event that any of the
required policies of insurance are written on a claims made basis, then such policies shall be maintained during the entire term of this Agreement and for a period of not less than five (5) years following the termination or expiration of this
Agreement. 
 13.4.3 Each Party shall be named as an additional insured under the other Party’s Commercial General
Liability, Products Liability (as applicable) and Umbrella insurance policies to the extent permitted under such policies. Such additional insured status shall end upon the termination or expiration of this Agreement unless the insuring Party’s
policies are written on a claims made basis, in which case such additional insured status shall continue for the period of time that such insuring Party is required to maintain such insurance under the terms of this Agreement. 

13.4.4 Each Party will (a) furnish certificates of insurance to the other Party evidencing the required insurance and
additional insured status, as applicable, prior to the Effective Date and upon request thereafter and (b) provide the other Party with written notice at least thirty (30) days prior to the cancellation, non-renewal or material change in
such insurance that materially adversely affects the rights of the other Party hereunder. 
 14. DISPUTE RESOLUTION 

14.1 Exclusive Dispute Resolution Mechanism. The Parties agree that the procedures set forth in this Article 14 shall be the
exclusive mechanism for resolving any disputes, controversies, or claims (collectively, “Disputes”) between the Parties that may arise from time to time pursuant to this Agreement relating to either Party’s rights and/or
obligations hereunder that cannot be resolved through good faith negotiation between the Parties. 
 14.2 Arbitration.

 14.2.1 Any and all unresolved Disputes, except as set forth in Section 14.3 or Section 14.4, shall be
exclusively and finally resolved by binding arbitration. 
 14.2.2 Any arbitration concerning a Dispute shall be
conducted in London, unless otherwise agreed to by the Parties in writing. Each and any arbitration shall be administered by the London Court of International Arbitration (“LCIA”), and shall be conducted in accordance with LCIA
Rules (the “Rules”), as such Rules may be amended from time to time. All arbitration proceedings will be conducted in the English language. 

14.2.3 Within ten (10) days after receipt of an arbitration notice from a Party, the Parties shall attempt in good faith to
agree on a single neutral arbitrator with relevant industry experience to conduct the arbitration. If the Parties do not agree on a single neutral arbitrator within ten (10) days after receipt of an arbitration notice, each Party shall select
one (1) arbitrator within fifteen (15) days after receipt of an arbitration notice and the two (2) Party-selected arbitrators shall select a third arbitrator with relevant industry experience to constitute a panel of

  

 32 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
three (3) arbitrators to conduct the arbitration in accordance with the Rules. In the event that the two (2) Party-selected arbitrators are unable to select the third arbitrator due to
lack of mutual consent, the Parties shall request the LCIA to appoint an independent and qualified third arbitrator and an appointment made by LCIA pursuant to such request shall be binding on both the Parties. In the event that only one of the
Parties selects an arbitrator within fifteen (15) days after receipt of an arbitration notice, then such arbitrator shall be entitled to act as the sole arbitrator to resolve the Dispute or any and all unresolved issues subject to the
arbitration. Each and every arbitrator of the arbitration panel conducting the arbitration must and shall agree to render an opinion within twenty (20) days after the final hearing before the panel. 

14.2.4 The decision or award of the arbitrator(s) shall be final, binding, and incontestable and may be used as a basis for
judgment thereon in any jurisdiction. To the full extent permissible under Applicable Law, the Parties hereby expressly agree to waive the right to appeal from the decision of the arbitrator(s), there shall be no appeal to any court or other
authority (government or private) from the decision of the arbitrator(s), and the Parties shall not dispute nor question the validity of such decision or award before any regulatory or other authority in any jurisdiction where enforcement action is
taken by the Party in whose favor the decision or award is rendered, except in the case of fraud. The arbitrator(s) shall, upon the request of either Party, issue a written opinion of the findings of fact and conclusions of law and shall deliver a
copy to each of the Parties. Each Party shall bear its own costs and attorney’s fees, and the Parties shall equally bear the fees, costs, and expenses of the arbitrator(s) and the arbitration proceedings; provided, however, that
the arbitrator(s) may exercise discretion to award costs, including attorney’s fees, to the prevailing Party. Without limiting any other remedies that may be available under Applicable Law, the arbitrator(s) shall have no authority to award
provisional remedies of any nature whatsoever, or punitive, special, consequential, or any other similar form of damages except as expressly set forth in Section 16.2. 

14.3 Preliminary Injunctions. Notwithstanding anything in this Agreement to the contrary, and pursuant to Section 10.5, a
Party may seek a temporary restraining order or a preliminary injunction from any court of competent jurisdiction in order to prevent immediate and irreparable injury, loss, or damage on a provisional basis, pending the decision of the arbitrator(s)
on the ultimate merits of any Dispute. 
 14.4 Patent Disputes. Notwithstanding anything in this Agreement to the
contrary, any and all issues regarding the scope, construction, validity, and enforceability of one or more Patents shall be determined in a court of competent jurisdiction under the local patent laws of the jurisdictions having issued the Patent or
Patents in question. 
 14.5 Confidentiality. All proceedings and decisions of the arbitrator(s) shall be deemed
Confidential Information of each of the Parties, and shall be subject to the terms and conditions of Article 10. 
 15. TERM,
TERMINATION AND BUY-OUT RIGHT 
 15.1 Term. The term of this Agreement shall commence on the Effective Date and
continue in full force and effect on a Product-by-Product basis until the tenth anniversary of the 
  

 33 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
Effective Date, unless extended by mutual agreement of the Parties and/or unless terminated at an earlier date in accordance with Sections 15.2 or 15.3 (the “Term”). 

15.2 Termination for Cause. If a Party breaches any material term or condition of this Agreement, the other Party may notify the
breaching Party in writing of such breach, in accordance with Section 16.7, setting forth the nature of the breach in reasonable detail. If the breaching Party fails to cure such breach (if curable) within thirty (30) days after the
receipt of the foregoing notice from the non-breaching Party, the non-breaching Party may terminate this Agreement effective immediately upon delivery of a second written notice to the breaching Party. Any breach by an Affiliate of Arch of any of
the terms and conditions of this Agreement shall constitute a breach of this Agreement by Arch. In the event of a non-curable breach, the non-breaching Party shall be entitled, in the non-breaching Party’s sole discretion, to immediately
terminate on a Product-by-Product basis or this Agreement in its entirety. 
 15.3 Termination for Insolvency. To the
extent permitted under Applicable Law, a Party may terminate this Agreement upon thirty (30) days written notice to the other Party on or after the occurrence of any of the following events: (a) the appointment of a trustee, receiver or
custodian for all or substantially all of the property of the other Party, or for any lesser portion of such property, if the result materially and adversely affects the ability of the other Party to fulfill its obligations hereunder, which
appointment is not dismissed within sixty (60) days; (b) the determination by a court or tribunal of competent jurisdiction that the other Party is insolvent such that a Party’s liabilities exceed the fair market value of its assets;
(c) the filing of a petition for relief in bankruptcy by the other Party on its own behalf, or the filing of any such petition against the other Party if the proceeding is not dismissed or withdrawn within sixty (60) days thereafter;
(d) an assignment by the other Party for the benefit of creditors; or (e) the dissolution or liquidation of the other Party. 

15.4 Effect of Expiration or Termination. 

15.4.1 Upon expiration of this Agreement, on a Product-by-Product basis, pursuant to Section 15.1 (but not early termination),
the licenses in respect of such Product under Section 2.2 shall terminate unless Arch exercises the right provided in Section 15.5 of this Agreement. 

15.4.2 Upon expiration or termination of this Agreement by either Party for any reason, each Party shall promptly return, or
destroy and provide written certification of such destruction by a duly authorized officer of such Party, any and all Confidential Information of the other Party in such first Party’s possession or control at the time of such expiration or
termination, provided however, if Arch is entitled to exercise its right under Section 15.5 and exercised such right, then Arch shall not be required to return or destroy any Confidential Information in Arch’s possession at the time of
such expiration or termination which Confidential Information is used to practice or exploit any right acquired by the exercise of the Option pursuant to Section 15.5 below. 

15.4.3 Expiration or termination of this Agreement for any reason shall not (a) release any Party from any obligation that
has accrued prior to the effective date of such expiration or termination (including the obligation to pay amounts accrued and due under this 

 

 34 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
Agreement prior to the expiration or termination date but which are unpaid or become payable thereafter), (b) preclude any Party from claiming any other damages, compensation, or relief that
it may be entitled to upon such expiration or termination, or (c) terminate any right to obtain performance of any obligation provided for in this Agreement that shall survive expiration or termination. 

15.5 Right to acquire Product license on the occurrence of any Buy-Out Event. On the occurrence of any Buy-Out Event, Arch
shall have the right, but not the obligation, to acquire an irrevocable, royalty-free, perpetual and non-exclusive license on a Product-by-Product basis, to Codexis IP Rights, Codexis Process and Codexis Improvements covering the manufacture of such
Codexis Enzymes that are used to further manufacture such Product for a one-time lump-sum consideration of [*] per Product (the “Option”). The Option shall expire in ninety (90) days from the day of occurrence of the
Buy-Out Event unless Arch exercises its Option and makes the payment of the said consideration to Codexis within such ninety (90) day period. During such ninety (90) day period, if the Buy-Out Event is other than bankruptcy or insolvency
of Codexis or expiration of this Agreement, Codexis shall continue to perform its obligations under the Agreement in respect of the Products not subject to the Buy-Out Event. The payment above shall be Codexis’ sole compensation for such
Option-exercise by Arch. In the event Arch exercises its Option, Codexis shall render reasonable support to allow Arch to effectively utilize the rights acquired by the Option exercise, including without limitation, introduction of appropriate
contacts and technology support; provided, however, such support shall only be provided during (and only during) scale up at Arch or a contract manufacturing organization designated by Arch and in no event for a period longer than eight
(8) weeks. Codexis’ obligations in respect of such support shall be limited to (i) phone and email support and (ii) onsite support limited to ten (10) man-hours per week provided that Arch cover all out-of-pocket travel and
boarding expenses. Any license granted to Arch pursuant to this Section 15.5 shall be subject to the following restrictions: (i) Arch may not manufacture any Codexis Enzymes for Third Parties; (ii) Arch may only manufacture Codexis
Enzymes solely for use by Arch to manufacture Products for sale by Arch; (iii) Arch may not sublicense any of the rights granted by Codexis to Arch. Furthermore, any license granted to Arch pursuant to this Section 15.5 shall not affect
(i) Codexis’ ownership rights in (or Codexis’ rights to grant additional licenses to) Codexis IP Rights, Codexis Process and Codexis Improvements or (ii) Codexis’ right to manufacture Codexis Enzymes that are subject to the
product or (iii) Codexis’ right to purchase Products from Third Parties and sell Products to Codexis Customers. 

15.6 Survival. In addition to any provisions which by their terms survive termination or expiration of this Agreement, Articles 1,
10 (for the period set forth in Section 10.7), 14 and 16 and Sections 2.9, 2.15 (for the period set forth therein), 3.12.6, 9.3, 11.1, 11.2, 11.3, 11.4, 11.5, 12.5, 13.1, 13.2, 13.3, 13.4 (for the period set forth therein) and 15.6 shall
survive expiration or termination of this Agreement, as applicable. 
 16. MISCELLANEOUS 

16.1 Further Assurances. From time to time on and after the Effective Date, each Party shall at the reasonable request of the other
Party (a) deliver to the other Party such records, data, or other documents; (b) execute, and deliver or cause to be delivered, all assignments, 

 

 35 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 
consents, documents or further instruments of transfer or license; and (c) take or cause to be taken all other actions as such other Party may reasonably deem necessary or desirable in order
for such Party to obtain the full benefits of this Agreement and the transactions contemplated hereby; each to the extent as required under the provisions of this Agreement. 

16.2 Limitation of Liability. EXCEPT FOR BREACH OF ARTICLE 10, CLAIMS OF A THIRD PARTY THAT ARE SUBJECT TO INDEMNIFICATION UNDER
ARTICLE 13, OR WITH RESPECT TO UNAUTHORIZED EXPLOITATION OF CODEXIS’ INTELLECTUAL PROPERTY RIGHTS, INCLUDING WITHOUT LIMITATION, BREACH OF 12.4.1 AND 12.4.2, IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR INCIDENTAL, CONSEQUENTIAL, INDIRECT,
PUNITIVE, EXEMPLARY, OR SPECIAL DAMAGES OF THE OTHER PARTY ARISING OUT OF OR RELATED TO THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY, WHETHER FORESEEABLE OR NOT. 

16.3 Governing Law. This Agreement shall be governed by, and construed and interpreted in accordance with, the internal laws of
the State of New York, United States of America, without giving effect to any choice of law rule that would cause the application of the laws of any jurisdiction other than the internal laws of such State to the rights and duties of the Parties.

 16.4 Force Majeure. Except for the payment of money, neither Party shall be held responsible for any delay or failure
in performance hereunder caused by strikes, embargoes, unexpected government requirements, civil or military authorities, acts of God, flood, earthquake, or by the public enemy or other causes reasonably beyond such Party’s control and without
such Party’s fault or negligence; provided, that the affected Party notifies the unaffected Party as soon as reasonably possible and resumes performance hereunder as soon as reasonably possible following cessation of such force majeure
event; provided, further, that no such delay or failure in performance shall continue for more than three (3) months. In the event that a delay or failure in performance by a Party under this Section 16.4 continues longer
than three (3) months, the other Party may terminate this Agreement in accordance with the terms and conditions of Section 15.2. 

16.5 Independent Contractors. Nothing contained in this Agreement shall be deemed to constitute a partnership, joint venture,
association of persons, agency or any other such relationship of similar nature, between the Parties. Nothing in this Agreement shall constitute or be deemed to or is intended to constitute Arch as an agent of Codexis or Codexis as an agent of Arch.
Neither Party shall: (a) enter into a contract in the name of or purporting to be made on behalf of the other Party unless to the extent as may be authorized under any agreement entered into between the Parties; (b) by any act, pledge the
credit of the other Party or impose or attempt to impose any contractual obligations on the other Party; or (c) either in its own office, factories or depots or on invoices, bill heads or letter papers or any other place or by any other means,
oral or written, make any statement to the effect or representation calculated or liable to induce others to believe that it is the agent of the other Party. 
  

 36 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 16.6 Assignment. This Agreement is binding upon and inures to the benefit of the
Parties, and to their permitted successors and assigns. Neither Party may transfer or assign its rights and obligations under this Agreement to a Third Party without the prior written consent of the other Party. Notwithstanding the foregoing, each
of the Parties shall have the right to transfer or assign its rights and obligations under this Agreement, without consent, to an Affiliate or a successor to all or substantially all of its business or assets relating to this Agreement whether by
operation of law, sale, merger, or otherwise. Any assignment not in conformance with this Section 16.6 shall be null, void, and of no legal effect. 

16.7 Notices. Any notice, report, communication, or consent required or permitted by this Agreement shall be in writing and shall
be sent (a) by prepaid registered or certified mail, return receipt requested, (b) by overnight express delivery service by a nationally recognized courier, or (c) via confirmed facsimile, followed within five (5) days by a copy
delivered in accordance with this Section 16.7, addressed to the other Party at the address shown below or at such other address as such Party gives notice hereunder. Such notice will be deemed to have been given when delivered or, if delivery
is not accomplished by some fault of the addressee, when tendered. 
  

			
	If to Arch:	    	Arch Pharmalabs Limited
		    	H wing, 4th Floor
		    	Tex Centre
		    	Off Saki Vihar Road
		    	Chandivali, Mumbai- 400072
		    	India
		    	Attn: Company Secretary
		    	Facsimile: +912228471234
		
	With a copy to:	    	Arch Pharmalabs Limited
		    	H wing, 4th Floor
		    	Tex Centre
		    	Off Saki Vihar Road
		    	Chandivali, Mumbai- 400072
		    	India
		    	Attn: Chairman and Managing Director
		    	Facsimile: +912228471234
		
	If to Codexis:	    	Codexis, Inc.
		    	200 Penobscot Drive
		    	Redwood City, California 94063
		    	USA
		    	Attn: President, Pharmaceuticals
		    	Facsimile: 1-650-421-8134
		
	With a copy to:	    	Codexis, Inc.

  

 37 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

			
		  	200 Penobscot Drive
		  	Redwood City, California 94063
		  	USA
		  	Attn: General Counsel
		  	Facsimile: 1-650-421-8108

 16.8
Severability. If any provision of this Agreement is found by a court to be void, invalid, or unenforceable, such provision shall be reformed to comply with Applicable Law or stricken if not so conformable, so as not to affect the validity or
enforceability of this Agreement; provided that no such reformation or striking shall be effective if the result materially changes the economic benefit of this Agreement to either Party. If any provision of this Agreement becomes or is declared by
a court of competent jurisdiction to be void, invalid, or unenforceable, and reformation or striking of such provision would materially change the economic benefit of this Agreement to either Party, the Parties shall modify such provision in
accordance with Section 16.9 to obtain a legal, valid, and enforceable provision and provide an economic benefit to the Parties that most nearly effects the Parties’ intent on entering into this Agreement. 

16.9 Modifications; Waivers. This Agreement may not be altered, amended, supplemented, or modified in any way except by a writing
signed by each Party. The failure of a Party to enforce any rights or provisions of this Agreement shall not be construed to be a waiver of such rights or provisions, or a waiver by such Party to thereafter enforce such rights or provision or any
other rights or provisions hereunder. 
 16.10 No Third Party Beneficiaries. This Agreement is neither expressly nor
impliedly made for the benefit of any party other than those executing it. 
 16.11 Interpretation. 

(a) Captions and Headings. The captions and headings of clauses contained in this Agreement preceding the text of the articles,
sections, subsections, and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction. 

(b) Singular and Plural. All references in this Agreement to the singular shall include the plural where applicable, and all
references to gender shall include both genders and the neuter. 
 (c) Articles, Sections, and Subsections. Unless
otherwise specified, references in this Agreement to any article shall include all sections, subsections, and paragraphs in such article; references in this Agreement to any section shall include all subsections and paragraphs in such section; and
references in this Agreement to any subsection shall include all paragraphs in such subsection. 
 (d) Days. All
references to days in this Agreement shall mean calendar days, unless otherwise specified. 
  

 38 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 (e) Ambiguities. The Parties jointly drafted this Agreement. Ambiguities and
uncertainties in this Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist. 

16.12 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original and all of which
together shall constitute one instrument. 
 16.13 Entire Agreement. The Parties acknowledge that this Agreement,
including, for clarity, the preamble, recitals, and exhibits attached hereto, together with accepted Product Purchase Orders and accepted Enzyme Purchase Orders, a letter agreement between Codexis and Arch dated December 22, 2009, the MSA and
any other agreements entered into by the Parties contemporaneously with this Agreement sets forth the entire agreement and understanding of the Parties as to the subject matter hereof, and supersedes all prior and contemporaneous discussions,
agreements, and writings with respect hereto with respect to the subject matter hereof, including without limitation the 2008 Arch Agreements, which are hereby terminated in their entirety. No trade customs, courses of dealing or courses of
performance by the Parties shall be relevant to modify any term(s) used in this Agreement. 
 [Signature page follows]

  

 39 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 IN WITNESS WHEREOF, Arch and Codexis have executed this Agreement by their respective
duly authorized representatives as of the Effective Date. 
  

			
	CODEXIS, INC.
	(“Codexis”)
		
	By:	 	 /s/ Joseph Sarret

	Name:	 	 Joseph Sarret

	Title:	 	 President, Pharma Services & Enzyme Products

	
	ARCH PHARMALABS LIMITED
	(“Arch”)
		
	By:	 	 /s/ Ajit Kamath

	Name:	 	 Ajit Kamath

	Title:	 	 Chairman & Managing Director.

 

 [*] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Exhibit 1.8 

Arch Trademarks 

 

 

  

 [*] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Exhibit 1.17 

Codexis Enzymes 

[*] 
  

 2 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 Exhibit 1.24 

Codexis Trademarks 

 

 

  

 3 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 Exhibit 1.45 

Products 
 Category I
- APIs 
  

	 	•	 	 [*] 

Category II - intermediates 
  

	 	•	 	 [*] 

  

 4 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 Exhibit 2.14 

Specifications for [*] shall be provided by Codexis within six (6) months after the Effective Date. Specifications for remaining Codexis
Enzymes are as set forth below: 
 PRODUCT SPECIFICATIONS 

[*] 

Lyophilized Enzyme Powder 
  

					
	 TEST DESCRIPTION
	 	 SPECIFICATION
	 	 TEST METHOD

	 1. Appearance
	 	[*]	 	QCP-029
			
	 2. Specific Activity
	 	[*]	 	QCP-001
			
	 3. Moisture
	 	[*]	 	QCP-025

  

 5 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 PRODUCT SPECIFICATIONS 

[*] 

Lyophilized Enzyme Powder 
  

					
	 TEST DESCRIPTION
	 	 SPECIFICATION
	 	 TEST METHOD

	 1. Appearance
	 	[*]	 	QCP-029
			
	 2. Conversion (24 hours)
	 	[*]	 	QCP-019
			
	 3. Moisture
	 	[*]	 	QCP-025

  

 6 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 PRODUCT SPECIFICATIONS 

[*] 

Lyophilized Enzyme Powder 
  

					
	 TEST DESCRIPTION
	 	 SPECIFICATION
	 	 TEST METHOD

	 1. Appearance
	 	[*]	 	QCP-029
			
	 2. Percent Conversion
	 	[*]	 	QCP-027
			
	 3. Moisture
	 	[*]	 	QCP-025

  

 7 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 PRODUCT SPECIFICATIONS 

[*] 

Lyophilized Enzyme Powder 
  

					
	 TEST DESCRIPTION
	 	 SPECIFICATION
	 	 TEST METHOD

	 1. Appearance
	 	[*]	 	QCP-029
			
	 2. Specific Activity
	 	[*]	 	QCP-021
			
	 3. Moisture
	 	[*]	 	QCP-025

  

 8 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 PRODUCT SPECIFICATIONS 

[*] 

Lyophilized Enzyme Powder 
  

					
	 TEST DESCRIPTION
	 	 SPECIFICATION
	 	 TEST METHOD

	 1. Appearance
	 	[*]	 	QCP-029
			
	 2. Specific Activity
	 	[*]	 	QCP-002
			
	 3. Moisture
	 	[*]	 	QCP-025

  

 9 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 PRODUCT SPECIFICATIONS 

[*] 

Lyophilized Enzyme Powder 
  

					
	 TEST DESCRIPTION
	 	 SPECIFICATION
	 	 TEST METHOD

	 1. Appearance
	 	[*]	 	QCP-029
			
	 2. Specific Activity
	 	[*]	 	QCP-013
			
	 3. Moisture
	 	[*]	 	QCP-025

  

 10 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 Exhibit 3.4 

Product Labeling 

Written Product labeling instructions to be provided directly by Codexis to Arch. 

 

 [*] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Exhibit 5.4 

Arch’s Monthly Reports To Codexis 

To facilitate Codexis’ various accounting and operational requirements, Arch will provide Codexis with the following monthly
information on both a Codexis Enzyme-by-Codexis Enzyme and a Product-by-Product basis. This information will be delivered by Arch to Codexis in a mutually-acceptable electronic format on or around the
15th of the month and within two (2) Business Days
after the end of each month: 
  

	 	A.	Opening Codexis Enzyme and Product Inventory Balance (Kilograms), by Product 

 

	 	B.	Product Manufactured (Kilograms) and Codexis Enzyme Used (Kilograms), by Product 

 

	 	C.	Total Codexis Enzyme scrapped, by Product 

  

	 	D.	Product Sold to Codexis (Kilograms) 

  

	 	E.	Product Sold by Arch to customers other than Codexis (Kilograms) 

  

	 	F.	Ending Codexis Enzyme and Product Inventory Balance (Kilograms), by Product 

 

	 	G.	Codexis Enzyme Loading and scrap loss at each stage of manufacturing with respect to each Product 

 

	 	H.	Site to site transfer information by enzyme, stage intermediate and product. 

  

 [*] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Exhibit 13.4.1 

Insurance 

CODEXIS INSURANCE TYPES AND LIMITS 
  

			
	 Type of Insurance
	 	 Limits of Liability

	Commercial General Liability (including contractual liability but excluding Product Liability) with bodily injury, death and property damage coverage limits as
specified	 	Combined single limit of not less than $1,000,000 per occurrence and $2,000,000 in the aggregate
		
	Product Liability with bodily injury, death and property damage coverage limits as specified	 	Either (a) any limit mutually agreed to by the Parties, (b) any limit required by a customer that requests to purchase at least $3,000,000 worth of Products collectively from the
Parties and their Affiliates in any one (1) year period, or (c) at the point at which Parties and their Affiliates collectively have sold an aggregate amount of at least $30,000,000 worth of Products in any one (1) year period, a combined single
limit of not less than $10,000,000 per occurrence and in the aggregate
		
	Umbrella Policy with bodily injury, death and property damage coverage limits as specified (does not include Product Liability)	 	 Combined single limit of not less than $1,000,000 per occurrence and

$2,000,000 in the aggregate

		
	Worker’s Compensation (work injury)	 	$1,000,000 per accident

  

 [*] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 ARCH INSURANCE TYPES AND LIMITS 

 

					
	 Particulars
	  	Amount in INR	  	Amount in USD $
	 Fixed Assets - Movable - Office Protection
	  	103846006	  	2257522
	 Fixed Assets - Movable & Immovable
	  	5260374888	  	114355976
	 Sub-total - Fixed Assets
	  	5364220894	  	116613498
			
	 Current Assets - Movable - Stock at factories, Warehouses, Goods-in-transit
	  	4045000000	  	87934783
	 Current Assets - Fidelity & Money
	  	303000000	  	6586957
	 Sub-Total - Current Assets
	  	4348000000	  	94521740
			
	 Total - Commercial General Liability
	  	9712220894	  	211135238
			
	 Workmen’s Compensation
	  	24000000	  	521739
	 Personal Accident
	  	400800000	  	8713043
	 Total - Workmen & Employees
	  	424800000	  	9234782
			
	 Public Liability
	  	1110000000	  	24130435
	 Total Umbrella Policy
	  	1110000000	  	24130435
			
	 Total Coverage
	  	11247020894	  	244500454

 (Assumption USD $1= INR
46) 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00172-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00172-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00172-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00172-of-00352.parquet"}]]